



Schulich School of Medicine & Dentistry
Professional Curriculum Vitae
FEBRUARY 4, 2015

DR. GERALD B. BROCK
MD, FRCSC

Professor - Department of Surgery
Professor - Department of Obstetrics & Gynaecology

PERSONAL SUMMARY

Name	Gerald B. Brock
Date of Birth	1959 Apr 7
Languages	English, Understood, Spoken, Read, Written French, Understood, Spoken, Read, Written

BIO SKETCH

Dr. Gerald Brock is a Professor in the Department of Surgery, Division of Urology, at St. Joseph's Health Centre in London, Ontario. Dr. Brock is the Program Director for the Urology Residency Training Program at The University of Western Ontario. Presently, he is the Secretary of the Sexual Medicine Society of North America, the Vice President of the Canadian Urology Association running the Office of Education, and is the Scientific Chair of the Society for the Study of the Aging Male. Dr. Brock has served as Chair of the Canadian Male Sexual Health Council (affiliate of the Canadian Urology Association - CUA), as well as the Guidelines Committees of the CUA and CUA Scholarship Foundation Administrative chair. In addition to his role as Urology Program Director, he runs a productive basic science research lab at the Lawson Research Institute focusing on the impact of disease states on erectile mechanisms. His lab has received continuous peer-reviewed funding for two decades and currently serves as a vehicle to train residents and fellows in microsurgery, use of animal models of erectile dysfunction and gaining a greater understanding of basic research methodology.

Dr. Brock is the author of over 150 publications, 25 book chapters, numerous abstracts and more than 20 research awards from national and international research organizations. Over the past ten years, he has been invited to speak across Canada, the USA, Europe, Africa and Asia. Dr. Brock's work in urology and erectile dysfunction is acknowledged by his role as section editor of the CUA Journal, as well as an editorial board member of multiple other scientific journals.

He has run an active andrology fellowship combining basic animal physiology with clinical exposure ranging from 1-2 years for the past 15 years with graduates of urology programs from North America, Asia and beyond.

EDUCATION AND QUALIFICATIONS

Degrees and Diplomas

1982 - 1986	MD, McGill Medical School, Montreal, CM, Physiology
1978 - 1981	BSc, McGill University, Montreal, Physiology

Specialized Training

1991 - 1993	University of California, San Francisco, Program Co-Directors: Dr. T.F. Lue, Dr. E. Tanagho, Neuro-urology
1986 - 1991	McGill University, Program Director: Dr. M. Elhilali, Urology Residency Program

APPOINTMENTS AND HONOURS

Appointments

Current Appointment(s)

Western Appointments

Primary Appointment

2006 - present Professor, Department of Surgery, Division of Urology, Schulich School of Medicine & Dentistry, The University of Western Ontario

Other Appointment(s)

2006 - present Professor, Department of Obstetrics & Gynaecology, Urogynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario

Hospital Appointments

Primary Appointment

present Urologist, St. Joseph's Health Care London, Department of Surgery, Division of Urology

Previous Appointment(s)

Western Appointments

Primary Appointment

2003 - 2006 Associate Professor, Department of Surgery, Division of Urology, Schulich School of Medicine & Dentistry, The University of Western Ontario

1998 - 2003 Assistant Professor, Department of Surgery, Division of Urology, Schulich School of Medicine & Dentistry, The University of Western Ontario

Other Appointment(s)

2003 - 2006 Associate Professor, Department of Obstetrics & Gynaecology, Urogynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario

2000 - 2003 Assistant Professor, Department of Obstetrics & Gynaecology, Urogynaecology, Schulich School of Medicine & Dentistry, The University of Western Ontario

Previous Positions Held

Previous Academic Position(s)

2009 - 2014 Program Director, Schulich School of Medicine and Dentistry, Western University, Urology

1998 Associate Professor, McGill University, Montreal, Quebec, Canada

1983 - 1998 Assistant Professor, McGill University, Montreal, Quebec, Canada

Honours

Received

2008 - 2009	Urology Teaching Award, Urology Residents Teaching Award
2006	First Prize, Canadian Urology Association Essay Contest 2006, Kok BL, DeYoung L, Brock GB. Development of a new diagnostic approach using Seldi for Peyronie's Disease, Type: Distinction
2004	Endourology Prize (Second Prize)
1998	Basic Research Prize, Canadian Urology Association, Halifax, N.S.
1998	Honorable Mention G. Brock, Supervisor, Jack Lapidès Essay Contest in Neuro-Urology, San Diego
1998	Resident Prize. G. Brock, Supervisor, St. Lawrence Urology Group, Annual Meeting
1998	Resident Prize. G. Brock, Supervisor. Prairie Urologic Association Annual Meeting
1997	Basic Research Prize, Canadian Urology Association, Quebec City.
1997	First Place, Poster Prize, American Urology Association, New Orleans, LA, USA.
1996	Prix d'Excellence, Quebec Urology Association, Montreal, Quebec
1995	Prix d'Excellence, Quebec Urology Association, Montreal, Quebec
1995	Jack Lapidès Essay Contest, (2nd Prize), American Urological Association, Western Section, Las Vegas
1994	Jean-Paul Ginestie Prize, 5th World Meeting on Impotence, International Society for Impotence Research, Singapore
1994	American Urological Association Annual Meeting, North-Eastern Section, Lake George, New York
1994	Essay Contest (1st Prize), Canadian Urological Association, Jasper, Alberta
1994	2nd Prize, German Urological Association, Annual Meeting, Stuttgart, Germany
1993	Prix d'Excellence, Quebec Urologic Association Annual meeting, Montreal
1993	Joseph F. McCarthy Essay Contest, 1993 (1st Prize), American Urological Association, Western Section, Palm Desert CA
1993	1st Prize, American Urologic Society, Urodynamics Section, San Antonio (Texas)
1993	Essay Contest, (1st Prize), Canadian Urological Association, Montreal
1993	1st Prize, Miley B. Wesson Essay contest, American Urological Association, Western Section, Palm Desert CA
1992	Jean-Paul Ginestie Prize, 5th World meeting on Impotence, Milan, Italy

Teaching Awards

Received

2010 - 2011	USC Teaching honor role, Level: Postgraduate, USC Teaching honor role, Scope: Faculty, Graduate and Postdoctoral Studies, medicine, Canada
-------------	--

2008 - 2009	USC Teaching honor role, Level: Postgraduate, USC Teaching honor role, Scope: Faculty, Graduate and Postdoctoral Studies, medicine, Canada
2008 - 2009	Teaching award, Level: Postgraduate, Urology Residents Teaching Award -2008-2009, Sugery, Urology

SERVICE AND ADMINISTRATION

Professional Affiliations and Activities

Professional Associations

2001 - present	Member, American Society of Andrology
2001 - present	Member, Canadian Urology Research Consortium
1998 - present	Member, Sexual Medicine Society of North America-SMS, (Affiliate of the AUA)
1997 - present	Member, Canadian Male Sexual Health Council, (Affiliate of the CUA)
1991 - present	Member, Canadian Urological Association
1991 - present	Member, American Urological Association
1991 - present	Member, Canadian Medical Association
1991 - present	Member, Northeastern Section of the American Urological Association

Administrative Committees

International

SMSNA- affiliate of the AUA

2010 - 2013	Secretary, Sexual Medicine Society of North America
2007 - 2013	Fellowship Chair, Sexual Medicine Society of North America
2004 - 2013	Board of Directors, Sexual Medicine Society of North America
2002 - 2013	Member, Nominating committee, Sexual Medicine Society of North America

SSMNA - affiliate of the AUA

2005 - present	Chair, ISSM International Consultation on Urological Disease
----------------	--

SSMNA- affiliate of the AUA

2007 - 2010	Website Chair, Sexual Medicine Society of North America
-------------	---

World Health Organization

1998 - 2003	Member, World Health Organization Consensus Panel on Impotence
-------------	--

National

- 2008 - 2009 Scientific Chair, Canadian Society for the Study of Aging
- 2008 - 2009 Treasurer, Canadian Urology Research Consortium (CURC)
- 1998 - 2000 Member, Heart and Stroke Foundation - Cardiovascular Safety - Viagra Panel

Canadian Male Sexual Health Council

- 2013 - present President, CMSHC

Canadian Urological Association

- 2011 - present Vice-President of Education, Canadian Urological Association
- 1997 - 1999 Past-Chair, Sexual Health Education Council
- 1997 - 1999 Member, Scholarship Committee, CUA
- 1996 - present Member, Canadian Urological Association
- 1996 - 2004 Member, Guidelines Committee, CUA
- 1996 - 2004 Member, CUA Executive

Canadian Urological Association Sexual Function (CUASF)

- 2008 - 2009 Chair, CUASF Scholarship Foundation
- 2005 - 2010 Chair, Administrative council

Canadian Urology Research Consortium (CURC)

- 2004 - present Treasurer, Clinical Trials Committee

Royal College of Physicians and Surgeons of Canada

- 2005 - 2010 Examiner
- 2000 - 2004 Corresponding Member, Test Committee

Local

St. Joseph's Health Care, London

- 2004 - 2014 Member, Department of Surgery – Finance Committee
- 2003 - 2014 Member, Urology Finance Committee

External

College Des Mediciens Du Quebec

- 1996 - 1998 Member, Examination Committee

McGill University

1994 - 1998 Urology in-training examiner, Examination Committee

Other

2005 Member, Clinical Investigators Steering Committee

RESEARCH AND SCHOLARLY ACTIVITIES

Research Endeavours

- 2006 - present Active Research and Patient Education, Penile rehabilitation through patient education and PDE5 inhibitor use in post prostatectomy patients; PDE5 inhibitor used in Peyronie's disease; Minimally invasive surgery for Peyronie's disease; Penile prosthesis in treating erectile dysfunction in post prostatectomy, diabetes and Peyronie's disease patients
- 2006 - present Basic Research, His basic research involves creating erectile dysfunction and peyronie's disease animal models and understanding the mechanism of the diseases and search new therapies for those conditions. Current project include: The use of new compound to enhance the topic treatment for erectile dysfunction; understand pathophysiology of Peyronie's disease; new therapies for Peyronie's disease.

Grants

Peer Reviewed

Active Grants

2014 Dec - 2016 Nov	Title: Water jet dissection of cavernous nerves: nerve injury
Role: Co-Investigator	Co-Investigators: H Alenezi, L De Young, G Brock
Principal Investigator: S Pautler	
Grant Total: \$20,000	Funding Source: Department of Surgery Internal Fund for Clinical Academic
Industry Grant: N	

Past Grants

2013 Jul - 2014 Jul	Title: Penile traction therapy in Peyronies: an animal model
Role: Principal Investigator	Funding Source: CMSHC
Principal Investigator: Brock G	
Grant Total: \$50,000	
Industry Grant: N	

2012 Apr - 2013 Apr	Title: A novel study evaluating the effect of penile traction therapy in Peyronie's disease: an animal model
Role: Principal Investigator	Funding Source: CMSHC
Principal Investigator: Brock G	
Grant Total: \$50,000	
Industry Grant: N	

2010 Apr - 2011 Jul	Title: Sexual Health among university students
Role: Principal Investigator	Funding Source: CMSHC
Principal Investigator: Brock G	
Grant Total: \$30,000 CAD	
Member Share: \$30,000.00	
Industry Grant: N	

2009 Mar - 2010 Feb	Title: Peyronie's disease: An Animal model of traction device use
Role: Principal Investigator	Co-Investigators: none
Principal Investigator: Gerald Brock	
Grant Total: \$50,000 CAD	
Member Share: \$50,000.00	
Industry Grant: N	Funding Source: CMSHC

2009 Jan - 2012 Dec	Title: Quality of Life Outcomes Following Robot Assisted Laparoscopic Radical Prostatectomy: A Pilot Project
Role: Collaborator	Co-Investigators: Gerald Brock, Hassan Razvi
Principal Investigator: Stephen Pautler	
Grant Total: \$43,000 CAD	
Member Share: \$43,000.00	
Industry Grant: N	Funding Source: SJHC Foundation Urology Endowment Fund

2008 Jul - 2009 Jul	Title: Peyronie's disease: An animal Model
Role: Principal Investigator	Funding Source: CMSHC
Principal Investigator:	
Grant Total: \$50,000 CAD	
Member Share: \$50,000.00	
Industry Grant: N	

2007 Jul - 2008 Jun	Title: An in-vivo telemetric study evaluating the cellular basis of erectile recovery post cavernous nerve injury using SELDI to define the Alterations in pr
Role: Principal Investigator	Funding Source: Canadian Male Sexual Health Council
Principal Investigator: Gerald Brock	
Grant Total: \$50,000 CAD	
Member Share: \$50,000.00	
Industry Grant: N	

2007 Jul - 2008 Jun	Title: A telemetric evaluating the cellular basis of erectile recovery post cavernous nerve injury an animal model
Role: Principal Investigator	Funding Source: Canadian Male Sexual Health Council
Principal Investigator: Gerald Brock	

Grant Total: \$23,000 CAD	
Member Share: \$23,000.00	
Industry Grant: N	

2005 Jul - 2006	Title: New SELDI software and technical support for projects to identify markers for renal calculi, Dupuytren's disease and Peyronie's disease Funding Source: Lawson Health Research Institute - IRF
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$7,000 CAD	
Industry Grant: N	

2005 Jul - 2005 Jul	Title: New SELDI software and technical support for projects to identify markers for renal calculi, Dupuytren's disease and Peyronie's disease Funding Source: The Lawson Health Research Institute IRF
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$15,000 CAD	
Industry Grant: N	

2002 Mar - 2003	Title: Vascular impact of diabetes and use of an animal model for VEGF Funding Source: Canadian Male Sexual Health Council
Role: Principal or Joint Investigator	
Principal Investigator: Brock G	
Grant Total: \$50,000 CAD	
Industry Grant: N	

Non-Peer Reviewed

Active Grants

2013 - 2016	Title: Impact of testosterone solution on total testosterone, sex drive and energy in hypogonadal men Funding Source: Eli Lilly Canada Inc.
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$67,529	
Industry Grant: Y	

2008 - present	Title: Dose response study of LY compounds and PDE5 inhibitor Tadalafil
Role: Principal Investigator	Funding Source: Eli Lilly Canada Inc.
Principal Investigator: Brock G	
Grant Total: \$97,500	
Member Share: \$97,500.00	
Industry Grant: Y	

Past Grants

2012 - 2014	Title: 2% testosterone solution - ejaculatory dysfunction - testosterone deficiency
Role: Principal Investigator	Funding Source: Eli Lilly Canada Inc.
Principal Investigator: Brock G	
Grant Total: \$73,940	
Industry Grant: Y	

2012 - 2013	Title: A Novel Study Evaluating The Effect of Penile Traction Therapy in Peyronie's Disease: An Animal Model
Role: Principal Investigator	Funding Source: Canadian Male Sexual Health Council
Principal Investigator: Brock G	
Grant Total: \$50,000	
Industry Grant: N	

2012 - 2013	Title: Evaluate efficacy and safety of testosterone gel
Role: Principal Investigator	Funding Source: Ferring Pharmaceuticals Inc
Principal Investigator: Brock G	
Grant Total: \$159,335	
Industry Grant: N	

2012 - 2013	Title: Extension trial to evaluate the safety of testosterone gel in hypogonadal men
Role: Principal Investigator	Funding Source: Ferring Pharmaceuticals Inc
Principal Investigator: Brock G	
Grant Total: \$56,257	

Industry Grant: Y	
--------------------------	--

2010 - 2011	Title: LY500307 for 24 weeks in men LUTS and prostatic enlargement secondary to BPH Funding Source: Eli Lilly
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$86,896	
Industry Grant: Y	

2009 - 2012	Title: Tadalafil in subjects undergoing bilateral nerve-sparing radical prostatectomy Funding Source: Eli Lilly Canada Inc.
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$202,205	
Industry Grant: Y	

2007 Jul - 2008 Jun	Title: Erectile function dose response study with two different NOS inducers along with one single dose of Tadalafil. Funding Source: Eli Lilly Canada Inc.
Role: Principal Site Investigator	
Principal Investigator:	
Grant Total: \$97,500	
Industry Grant: Y	

2007 - 2008	Title: Titan one touch release clinical trial Funding Source: Coloplast
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$20,000	
Industry Grant: Y	

2006 Mar - 2008	Title: A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" to Alpha-Blocker Study in Men with Persistent Overactive Bladder Symptoms of Urinary Frequency and Urgency with/Without Urgency Incontinence after previous Monotherapy with Alpha Blocker Funding Source: Pfizer Canada Inc.
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$33,708 CAD	
Industry Grant: Y	

2006 Feb - 2007	Title: A multi-centre parallel group flexible dose trial with a double-blind randomized placebo-controlled phase followed by an open-label phase to assess the impact of viagra on the sexual satisfaction of men with mild erectile dysfunction Funding Source: Pfizer Canada Inc.
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$19,050 CAD	
Industry Grant: Y	

2005 Mar - 2008	Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation Funding Source: Janssen-Ortho
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$65,730 CAD	
Industry Grant: Y	

2005 Mar - 2008	Title: A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function Funding Source: Bayer
Role: Principal or Joint Investigator	
Principal Investigator:	
Grant Total: \$111,780 CAD	
Industry Grant: Y	

2005 Mar - 2007 Mar	Title: A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 Funding Source: Pfizer
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$29,300 CAD	
Industry Grant: Y	

2005 Mar - 2005 Sep	Title: A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety and Toleration Of Differing Doses and Combinations Of Immediate And Modified Release Formulations Of UK-369,003 And Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction Funding Source: Pfizer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2005 Feb - 2005 Sep	Title: A phase 2, multi center, double blind, placebo controlled, flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation Funding Source: Pfizer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2004 Oct - 2005 Aug	Title: A phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy of oral UK-390,957 in men with pre-mature ejaculation Funding Source: Pfizer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2004 Oct - 2005 Jun	Title: A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to men with diabetes mellitus and Erectile Dysfunction Funding Source: Eli Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2004 - 2007	Title: The use of vardenafil and antioxidants in diabetes-associated erectile dysfunction: an animal study Funding Source: Bayer Health Care
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$44,000 CAD	
Industry Grant: Y	

2004 - 2007	Title: The use and efficacy of Sildenafil in diabetic men with erectile dysfunction: the impact on endothelial function, a pilot feasibility study Funding Source: Pfizer
Role: Principal Investigator	
Principal Investigator: Brock G	
Grant Total: \$83,000 CAD	
Industry Grant: Y	

2003 Dec - 2004 Jul	Title: A randomized, double blind, parallel group, multi-centre study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

	Funding Source: Bayer Canada Inc.
--	--

2003 Nov - 2008	Title: A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg) Funding Source: GlaxoSmithKline
Role: Principal or Joint Investigator	
Principal Investigator: Brock G	
Grant Total: \$153,000 CAD	
Industry Grant: Y	

2003 Jun - 2004 Jul	Title: A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 20mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20mg vardenafil Funding Source: GlaxoSmithKline
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2003 May - 2005 Jun	Title: Efficacy and Safety of Duloxetine Compared with Placebo in Women with Symptoms of Mixed Urinary Incontinence Funding Source: Eli Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2002 Jun - 2003 Aug	Title: A double-blind randomized parallel group study of Alfuzosin 10mg od verses placebo in the management of acute urinary retention in patients with a first episode due to BPH Funding Source: Sanofi-Synthelabo Canada
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2002 Jun - 2002	Title: Canadian study of the effectiveness of Alfuzosin 10mg once daily (Xatral®) for 3 months in improving lower urinary symptoms and maintaining sexual function in patients with benign prostatic hyperplasia Funding Source: Sanofi-Synthelabo Canada
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2001 Jul - 2002 Apr	Title: A phase III double blind randomized parallel study evaluating the safety and efficacy of UPRIMA® (apomorphine HCL tablets) sublingual (2 and 3 mg) in the
Role: Principal or Joint Investigator	

Principal Investigator:	treatment of male erectile dysfunction
Industry Grant: Y	
	Funding Source: TAPP

2001 Jul - 2002 Apr	Title: A randomized double blind multi centre fixed dose parallel group 12 month extension of study 10125 to investigate the safety and tolerability of the Phosphodiesterase Type V Vardenafil in the treatment of patients with erectile dysfunction of a total exposure time of 24 months Funding Source: Bayer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2001 Jul - 2001 Dec	Title: A multi center double blind randomized placebo and tamsulosin 0.4 mg controlled parallel group study to assess the efficacy and safety of "UK-338, 003 in patients with lower urinary tract symptoms due to benign prostatic obstruction Funding Source: Pfizer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2001 Mar - 2001 Dec	Title: A randomized double blind placebo controlled study of the efficacy and safety of IC351 (LY450190) administered ""on demand"" to patients with erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy Funding Source: Lilly ICOS
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2001 Feb - 2001 Dec	Title: A six month open label study of ""on demand"" therapy with IC351 for treatment of male erectile dysfunction Funding Source: Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2000 Dec - 2002 Jan	Title: A study on the American Medical Systems (AMS) 700 CX tm Inflatable Penile Prosthesis with Antibiotic Funding Source: AMS
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2000 Sep - 2001 May	Title: A randomized double blind placebo controlled study of efficacy and safety of IC351 (LY450190) administered
---------------------	--

Role: Principal or Joint Investigator	""on demand"" to patients with erectile dysfunction
Principal Investigator:	
Industry Grant: Y	
Funding Source: Lilly	

2000 Jul - 2001 Jul	Title: A randomized double-blind multi-centered fixed dose parallel group 12 month study to investigate the safety and tolerability of the Phosphodiesterase Type V Inhibitor BAY 38-9456 in the treatment of Erectile Dysfunction Funding Source: Bayer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2000 Jun - 2001 Jun	Title: A randomized double-blind placebo controlled multi centre fixed dose parallel group 3 month comparison study to investigate the efficacy and safety of the Phosphodiesterase Type V inhibitor BAY 38-9456 in males with erectile dysfunction following radical prostatectomy
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	
Funding Source: Bayer	

2000 Feb - 2002 Apr	Title: A phase III study of the efficacy of LY333531 (a protein kinase C β inhibitor) in males with diabetes and erectile dysfunction Funding Source: Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

2000 Feb - 2000 Oct	Title: A randomized double blind placebo controlled study of efficacy and safety of IC351 (LY450190) administered ""on demand"" to patients with erectile dysfunction (LVCE)
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	Funding Source: Lilly

2000 Jan - 2002 Sep	Title: A phase III study evaluating the safety and efficacy of UPRIMA™ (Apomorphine HCL) (2, 3, or 4 mg) compared to Viagra® (sildenafil citrate) (25, 50 or 100mg) in the treatment of male erectile dysfunction
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	
Funding Source: TAPP	

1999 Oct - 2002 Oct	Title: A one year open label study of ""on demand"" therapy with ICOS 351 for the treatment of male erectile
---------------------	---

Role: Principal or Joint Investigator	dysfunction Funding Source: Lilly
Principal Investigator:	
Industry Grant: Y	

1999 Oct - 2000 Jul	Title: A randomized double blind placebo controlled study of the efficacy and safety of IC351 (LY450190) administered ""on demand"" to patients with male erectile dysfunction Funding Source: Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

1999 Mar - 2001 Dec	Title: A double-blind, randomized, fixed-dose, placebo controlled study to assess the efficacy and safety of sildenafil in preventing erectile dysfunction in patients who have undergone a bilateral nerve sparing radical prostatectomy Funding Source: Pfizer
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

1999 Mar - 1999 Sep	Title: A randomized double blind placebo controlled study of IC351 (LY450190) administered ""on demand"" to patients with male erectile dysfunction Funding Source: Lilly
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

1999 Jan - 2001 Jan	Title: A fibrin glue delivery system for use in penile prosthesis Funding Source: American Medical Systems Inc.
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

1999 Jan - 2000 Jan	Title: An Animal study evaluating the altered penile micro environment in the elderly Funding Source: Pfizer Canada
Role: Principal Investigator	
Principal Investigator:	
Industry Grant: Y	

1998 Mar - 1998 Mar	Title: Investigator initiated basic study: Evaluating the impact of free oxygen nerve injury and the role of local scavenger delivery
Role: Principal Investigator	
Principal Investigator:	

Industry Grant: Y	Funding Source: Baxter Pharmaceutical
--------------------------	--

1996 Jul - 1998 Jun	Title: Diabetic induced erectile dysfunction: an animal model evaluating reactive oxygen species Funding Source: Canadian Diabetes Association
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: N	

1995 Oct - 1995 Oct	Title: The role of finasteride on nitric oxide synthase within the penis: an animal model Funding Source: FRSQ Industry - investigator award (Merck Frosst)
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: Y	

1995 Jul - 1997 Oct	Title: Investigator initiated trial evaluating the role of injection of PGE-1 in vasculogenic impotence Funding Source: Pharmacia & Upjohn
Role: Principal Investigator	
Principal Investigator:	
Industry Grant: Y	

1995 Jul - 1997 Oct	Title: The role of free oxygen radicals in erectile dysfunction Funding Source: Fonds de la Recherche en Sante du Quebec (FRSQ) Chercheur-Boursier
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: N	

1995 Jul - 1997 Jun	Title: The role of the nonadrenergic noncholinergic nervous system in erection Funding Source: Kidney Foundation of Canada
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: N	

1993 Jul - 1995 Jun	Title: The role of the nonadrenergic noncholinergic nervous system in erection Funding Source: Kidney Foundation of Canada
Role: Principal or Joint Investigator	
Principal Investigator:	
Industry Grant: N	

Clinical Trials

Non-Peer Reviewed

Active Clinical Trials

2011 - present	Title: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% Funding Source: Eli Lilly Canada Inc.
Role: Principal Site Investigator	
Principal Investigator: Brock G	
Grant Total: \$99,416	
Member Share: \$99,416.00	
Industry Grant: Y	

2009 - present	Title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil Funding Source: Eli Lilly Canada Inc.
Role: Principal Site Investigator	
Principal Investigator: Brock G	
Grant Total: \$115,178	
Member Share: \$115,178.00	
Industry Grant: Y	

Past Clinical Trials

2011	Title: Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks Funding Source: Eli Lilly Canada Inc.
Role: Principal Site Investigator	
Principal Investigator: Brock G	
Grant Total: \$90,298	
Member Share: \$90,298.00	
Industry Grant: Y	

Patents and Copyrights

Applied

- 2009/07 Patent, LINSE; laparoscopically introductible nerve stimulating electrode, UCSF; co-inventors: Wolf S, Gleason D, Lue TF, Carrol P
- Patent, A novel local drug delivery system for nerve trauma. Patent pending

Other Professional Activities

Research

Research Activity: Basic Research Focus, Elucidation of the role played by hormones on nitric oxide synthase and penile vascular flow.

Research Activity: Basic Research Focus, Assessment of the impact of vasodilators and vasoconstrictors on the penile circulation in normal and pathological states.

Research Activity: Basic Research Focus, Establishing the physiologic role played by the branch nerve fibres overlying the prostate and their contribution to erectile function.

Research Activity: Basic Research Focus, Determining the interaction between insulin-like-growth-factor and nitric oxide synthase in states of health and disease.

Research Activity: Basic Research Focus, Testing of animals with renal failure to evaluate the impact of an altered metabolic environment plays on NOS isotopes and erectile function.

Research Activity: Clinical Research Focus, Evaluation of the role of renal insufficiency on erectile function and the quality of life advantage provide through therapy.

Research Activity: Clinical Research Focus, Measurement of penile blood flow changes with vasoactive therapy in erectile dysfunction.

Research Activity: Clinical Research Focus, The impact of hormonal suppression on sexual functioning of men with advanced prostate cancer.

PUBLICATIONS

Peer Reviewed Publications

Journal Article

Published

1. Garcia FJ, Violette PD, **Brock GB**, Pautler SE. Predictive factors for return of erectile function in robotic radical prostatectomy: case series from a single centre. Int J Impot Res, 2015 Jan 7; 27 (1): 29-32, **Coauthor**, DOI: 10.1038/ijir.2014.20.
2. Kovac JR, DeYoung L, Lehmann KJ, Chung E, **Brock GB**. The effects of combined free radical scavenger and sildenafil therapy on age-associated erectile dysfunction: An animal model. Urol Ann, 2014 Oct; 6 (4): 314-320, **Senior Responsible Author**, DOI: 10.4103/0974-7796.
3. Nickel JC, **Brock GB**, Herschorn S, Dickson R, Henneges C, Viktrup L. Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia - integrated data from 1499 study participants. BJU Int, 2014 Sep; Sep 5, **Coauthor**, DOI: 10.1111/bju.12926.
4. Siddiqui KM, Billia M, Mazzola CR, Alzahrani A, **Brock GB**, Scilley C, Chin JL. Three-Year Outcomes of Recovery of Erectile

- Function after Open Radical Prostatectomy with Sural Nerve Grafting. *J Sex Med*, 2014 Aug; 11 (8): 2119-2124, **Coauthor**, DOI: 10.1111/jsm.12600.
5. **Brock G.** Diagnosing erectile dysfunction could save your patient's life. *CUAJ*, 2014 Jul; 8 (7-8 Suppl): S151-2, **Principal Author**, DOI: 10.5489/cuaj.2311.
 6. **Brock G.** CUA Office of Education: Expanding its scope. *CUAJ*, 2014 Mar 1; 8 (3-4): 83-90, **Principal Author**
 7. **Brock G**, Montorsi F, Buttner H, Hennes C, Mulhall J. Reply from authors re: Arthur L. Burnett. Erection rehabilitation after radical prostatectomy: definite purpose, indefinite strategy. *Eur Urol* 2014;65:597-8: although erection rehabilitation after prostatectomy remains indefinite, the most effective treatment, the earliest recovery, and the preservation of erectile function remain a definite goal. *Eur Urol*, 2014 Mar; 65 (3): 598-9, **Principal Author**, DOI: 10.1016/j.eururo.2013.11.015.
 8. **Brock G**, Montorsi F, Büttner H, Hennes C, Mulhall J. Reply from authors re: Arthur L. Burnett. Erection rehabilitation after radical prostatectomy: definite purpose, indefinite strategy. *Eur Urol* 2014;65:597-8: although erection rehabilitation after prostatectomy remains indefinite, the most effective treatment, the earliest recovery, and the preservation of erectile function remain a definite goal. *Eur Urol*, 2014 Mar; 65 (3): 598-9, **Principal Author**, DOI: 10.1016/j.eururo.201.
 9. Montorsi F, **Brock G**, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Hennes C, Dickson R, Büttner H. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). *Eur Urol*, 2014 Mar; 65 (3): 587-96, **Coauthor**, DOI: 10.1016/j.eururo.201.
 10. **Brock G.** Relationships with industry: a fine balance. *CUAJ*, 2014 Feb; 8 (1-2): 18-19, **Principal Author**, DOI: 10.5489/cuaj.1927.
 11. **Brock GB**, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. *J Urol*, 2014 Feb; 191 (2): 405-11, **Senior Responsible Author**, DOI: 10.1016/j.juro.2013.
 12. Chung E, Solomon M, DeYoung L, **Brock GB**. Clinical outcomes and patient satisfaction rates among elderly male aged ≥ 75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction. *World J Urol*, 2014 Feb; 32 (1): 173-7, **Senior Responsible Author**, DOI: 10.1007/s00345-013-1.
 13. **Brock G**, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. *BJU Int*, 2013 Nov; 112 (7): 990-997, **Senior Responsible Author**
 14. Chung E, Solomon M, DeYoung L, **Brock GB**. Comparison between AMS 700™ CX and Coloplast™ Titan inflatable penile prosthesis for Peyronie's disease treatment and remodeling: clinical outcomes and patient satisfaction. *J Sex Med*, 2013 Nov; 10 (11): 2855-60, **Principal Author**, DOI: 10.1111/jsm.12009.
 15. Darouiche RO, Bella AJ, Boone TB, **Brock G**, Broderick GA, Burnett AL, Carrion R, Carson C 3rd, Christine B, Dhabuwala CB, Hakim LS, Henry G, Jones LA, Khera M, Montague DK, Nehra A. North American consensus document on infection of penile prostheses. *Urology*, 2013 Oct; 82 (4): 937-42, **Coauthor**, DOI: 10.1016/j.urology.20.
 16. **Brock G**, Lee JKC. Sexual dysfunction in 2013: Advances in epidemiology, diagnosis and treatment. *Arab J Urol*. 2013 Sep; 11 (3): 194–202, **Senior Responsible Author**
 17. Lee KC, **Brock GB**. Daily dosing of PDE5 inhibitors: where does it fit in? *Curr Urol Rep*, 2013 Aug; 14 (4): 269-278, **Coauthor**
 18. Chung E, De Young L, Solomon M, **Brock GB**. Peyronie's Disease and Mechanotransduction: An In Vitro Analysis of the Cellular Changes to Peyronie's Disease in a Cell-Culture Strain System. *J Sex Med*, 2013 May; 10 (5): 1259-67, **Senior Responsible Author**
 19. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, **Brock G**, Harper W. Erectile dysfunction. *Can J Diabetes*, 2013 Apr 7; 37 (Suppl 1): S150-152, DOI: 10.1016/j.jcjd.
 20. Chung E, **Brock G**. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. *J Sex Med*. 2013 Feb; 10 Suppl 1: 102-11, **Senior**

Responsible Author, DOI: 10.1111/j.1743-6109.2012.03005.x.

21. Chung E, **Brock G**. Penile traction therapy and Peyronie's disease: a state of art review of the current literature. *Ther Adv Urol*. 2013 Feb; 5 (1): 59-65, **Senior Responsible Author**, DOI: 10.1177/1756287212454932.
22. Chung E, Garcia F, DeYoung L, Solomon M, **Brock GB**. A Comparative Study of the Efficacy of Intralesional Verapamil Versus Normal Saline Injection in a Novel Peyronie's Disease Animal Model: Assessment of Immunohistopathological Changes and Erectile Function Outcome. *J Urol Jan*, 2013 Jan; 189 (1): 380-384, **Principal Author**
23. Sikka SC, Hellstrom WJ, **Brock G**, Morales AM. Standardization of Vascular Assessment of Erectile Dysfunction: Standard Operating Procedures for Duplex Ultrasound. *J Sex Med*, 2013 Jan; 10 (1): 120-129, **Coauthor**
24. Porst H, Burnett A, **Brock G**, Ghanem H, Giuliano F, Gline S, Hellstrom W, Martin-Morales A, Salonia A, Sharlip I; ISSM Standards Committee for Sexual Medicine. SOP conservative (medical and mechanical) treatment of erectile dysfunction. *J Sex Med*, 2013 Jan; 10 (1): 130-171, **Coauthor**
25. Porst H, **Brock GB**, Kula K, Moncada I, Montorsi F, Basson BR, Kinchen K, Aversa A. Effects of Once-Daily Tadalafil on Treatment Satisfaction, Psychosocial Outcomes, Spontaneous Erections, and Measures of Endothelial Function in Men With Erectile Dysfunction But Naive to Phosphodiesterase Type 5 Inhibitors. *J androl*, 2012 Nov; 33 (6): 1305-1322, **Coauthor**
26. Chung E, Yan H, De Young L, **Brock GB**. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. *BJU Int*. 2012 Oct; 110 (8): 1201-5, **Senior Responsible Author**, DOI: 10.1111/j.1464-410X.2011.10851.x.
27. Ohi DA, **Brock G**, Ralph D, Bogache W, Jones L, Munarriz R, Levine L, Ritenour C. Prospective Evaluation of Patient Satisfaction, and Surgeon and Patient Trainer Assessment of the Coloplast Titan One Touch Release Three-Piece Inflatable Penile Prosthesis. *J Sex Med*, 2012 Sep; 9 (9): 2467-2474, **Coauthor**
28. Deyoung L, Chung E, Kovac JR, Romano W, **Brock GB**. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. *J Androl*. 2012 Mar; 33 (2): 176-80, **Senior Responsible Author**, DOI: 10.2164/jandrol.111.013367.
29. Domes T, Chung E, De Young L, MacLean NAB, Al-Shaiji TF, **Brock GB**. The clinical outcomes of intracavernosal injection in post-prostatectomy patients: a single centre experience. *Urology*, 2012 Jan; 9 (1): 26-33, **Coauthor**
30. Chung E, **Brock GB**. Sexual dysfunction in 2011: advances in epidemiology, pathophysiology and treatment. *Nat Rev Urol*. 2012 Jan; 9 (2): 66-8, **Senior Responsible Author**, DOI: 10.1038/nrurol.2011.223.
31. Jannini EA, Derogatis LR, Chung E, **Brock GB**. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. *J Sex Med* Jan, 2012 Jan; 79 (1): 150-155, **Senior Responsible Author**
32. Chung E, DeYoung L, **Brock GB**. Investigative models in erectile dysfunction: a state-of-the-art review of current animal models. *J Sex Med*. 2011 Dec; 8 (12): 3291-305, **Senior Responsible Author**
33. Chung E, De Young L, **Brock GB**. Penile duplex ultrasonography in men with Peyronie's disease: is it veno-occlusive dysfunction or poor cavernosal arterial inflow that contributes to erectile dysfunction? *J Sex Med*. 2011 Dec; 8 (12): 3446-51, **Senior Responsible Author**, DOI: 10.1111/j.1743-6109.2011.02501.x.
34. Chung E, **Brock GB**. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. *Curr Urol Rep*. 2011 Dec; 12 (6): 432-443, **Senior Responsible Author**
35. Chung E, De Young L, **Brock GB**. Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature. *Int J Impot Res*. 2011 Nov; 23 (6): 235-41, **Senior Responsible Author**, DOI: 10.1038/ijir.2011.36.
36. Chung E, **Brock GB**. Cryptorchidism and its impact on male fertility: A state of art review of current literature. *Can Urol Assoc J*. 2011 Jun; 5 (3): 210-4, **Senior Responsible Author**
37. Sadovsky R, **Brock GB**, Gray M, Jensen PK, Gutkin SW, Sorsaburu S. Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health. *J Am Acad Nurse*

- Pract. 2011 Jun; 23 (6): 320-30, **Coauthor**
38. Chung E, **Brock GB**. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011 Jun; 12 (8): 1341-1348, **Senior Responsible Author**
39. Chung E, Deyoung L, **Brock GB**. The Role of PDE5 Inhibitors in Penile Septal Scar Remodeling: Assessment of Clinical and Radiological Outcomes. J Sex Med. 2011 May; 8 (5): 1472-7, **Senior Responsible Author**
40. Donatucci CF, **Brock GB**, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011 Apr; 107 (7): 1110-6, **Coauthor**
41. Chung E, Clendinning E, Lessard L, **Brock G**. Five-year follow-up of peyronie's graft surgery: outcomes and patient satisfaction. J Sex Med. 2011 Feb; 8 (2): 594-600, **Coauthor**
42. Erdeljan P, **Brock G**, Pautler SE. Robot-assisted laparoscopic prostatectomy in patients with preexisting three-piece inflatable penile prosthesis. J Sex Med. 2011 Jan; 8 (1): 306-9, **Coauthor**
43. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, **Brock G**, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl-Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfau J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi-Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M. Summary of the recommendations on sexual dysfunctions in men. J Sex Med Nov, 2010 Nov; 7 (11): 3572-3588, **Coauthor**
44. Chung E, **Brock GB**. Delayed penile rehabilitation post radical prostatectomy. J Sex Med Oct, 2010 Oct; 7 (10): 3233-3236, **Senior Responsible Author**
45. Garcia FJ, **Brock G**. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol. 2010 May; 20 (3): 234-40, **Senior Responsible Author**
46. Mulhall JP, Bella AJ, Briganti A, McCullough A, **Brock G**. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010 Apr; 7 (4 Pt 2): 1687-98, **Senior Responsible Author**
47. Ng WK, Rosenblatt Y, **Brock GB**, O'Gorman DB, Siang Gan B. Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions. Can J Plast Surg Spring, 2010 Apr; 18 (1): e509, **Coauthor**
48. Chung E, **Brock GB**. Failure of pde5 inhibitor use: a case of non-responder? J Sex Med. 2010 Apr; 7 (4 pt 1): 1321-3, **Senior Responsible Author**
49. Althof SE, **Brock GB**, Rosen RC, Rowland DL, Aquilina JW, Rothman M, Tesfaye F, Bull S. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation. J Sex Med. 2010 Mar; 7 (6): 2243-52, **Coauthor**
50. Broderick GA, **Brock GB**, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010 Feb; 75 (6): 1452-8, **Coauthor**
51. De Young LX, Bella AJ, O'Gorman DB, Gan BS, Lim KB, **Brock GB**. Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med. 2010 Jan; 7 (1 Pt 1): 99-106, **Senior Responsible Author**
52. Al-Shaiji TF, Amann J, **Brock GB**. Fractured penis: diagnosis and management. J Sex Med. 2009 Dec; 6 (12): 3231-40,, **Coauthor**
53. Rubio-Aurioles E, Sand M, Terrein-Roccatti N, Dean J, Longworth J, Eardley I, **Brock G**, Lee J, de Montis IA, Rampazzo-Bonaldo C. Female Assessment of Male Erectile dysfunction detection scale (FAME): development and validation. J Sex Med. 2009 Aug; 6 (8): 2255-70, **Coauthor**
54. Al-Shaiji TF, **Brock GB**. Peyronie's disease: evolving surgical management and the role of phosphodiesterase 5 inhibitors. ScientificWorldJournal. 2009 Aug 31;9:822-45, **Senior Responsible Author**

55. Sadovsky R, **Brock GB**, Gutkin SW, Sorsaburu S. Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. *Int J Clin Pract*. 2009 Aug; 63 (8): 1214-30, **Coauthor**
56. **Brock GB**, Bénard F, Casey R, Elliott SL, Gajewski JB, Lee JC. Canadian male sexual health council survey to assess prevalence and treatment of premature ejaculation in Canada. *J Sex Med*. 2009 Aug; 6 (8): 2115-23, **Principal Author**
57. Al-Shaiji TF, **Brock GB**. Surgery: Centers of excellence for penile prosthesis: yes or no? *Nat Rev Urol*. 2009 Jul; 6 (7): 352-4, **Senior Responsible Author**
58. Tanguay S, Awde M, **Brock G**, Casey R, Kozak J, Lee J, Nickel JC, Saad F. Diagnosis and management of benign prostatic hyperplasia in primary care. *Can Urol Assoc J*. 2009 Jun; 3 (3 Suppl 2): S92-S100, **Coauthor**
59. **Brock G**, Glina S, Moncada I, Watts S, Xu L, Wolka A, Kopernicky V. Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction. *Urology*. 2009 Apr; 73 (4): 756-61, **Principal Author**
60. **Brock G**. Clinical case: 45-year-old male with penile pain (CME). *J Sex Med*. 2009 Apr; 6 (4): 900-1, **Principal Author**
61. Shaiji TA, Chb M, **Brock G**. Should penile rehabilitation become the norm following radical prostatectomy? *Can Urol Assoc J*. 2009 Feb; 3 (1): 50-3, **Senior Responsible Author**
62. Shaiji TA, Domes T, **Brock G**. Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art. *Can Urol Assoc J*. 2009 Feb; 3 (1): 37-48, **Senior Responsible Author**
63. **Brock G**, Glina S, Moncada I, Watts S, Xu L, Wolka A, Kopernicky V. Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction. *Urology*, 2009; 73 (4): 756-761, **Principal Author**
64. Al-Shaiji TF, **Brock GB**. Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. *Curr Pharm Des*. 2009; 15 (30): 3486-95, **Senior Responsible Author**
65. Montorsi F, **Brock G**, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. *Eur Urol*. 2008 Oct; 54 (4): 924-31, **Coauthor**
66. **Brock G**. Editorial comment on: Renal transplantation does not improve erectile function in hemodialysed patients. *Eur Urol*. 2008 Sep; 56 (6): 1054, **Principal Author**
67. Moreira ED, Glasser DB, King R, Duarte FG, Gingell C; GSSAB Investigators' Group. Sexual difficulties and help-seeking among mature adults in Australia: results from the Global Study of Sexual Attitudes and Behaviours. *Sex Health*. 2008 Sep; 5 (3): 227-34, **Coauthor**
68. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, **Brock G**; Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Int J Impot Res*. 2008 Sep; 20 (5): 479-86, **Senior Responsible Author**
69. De Young LX, Domes T, Lim K, Carson J, **Brock GB**. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. *Eur Urol*. 2008 Jul; 54 (1): 213-20, **Senior Responsible Author**
70. **Brock G**. Not perfect, but good enough. *Can Urol Assoc J*. 2008 Jun; 2 (3): 196, **Principal Author**
71. **Brock G**, Carrier S, Alarie P, Pommerville P, Casey R, Harris S, Ward R. The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. *J Sex Med*. 2008 Mar; 5 (3): 705-15, **Senior Responsible Author**
72. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, **Brock GB**, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. *Diabet Med*. 2008 Feb; 25 (2): 138-46, **Coauthor**

73. Adams MA, Brotto LA, Lowenstein L, **Brock GB**. Current literature review. *J Sex Med*. 2008; 5 (8): 1786-90, **Principal Author**
74. Glina S, Burnett AL, Becher E, **Brock G**, Hellstrom W. Priapism: reasons for failure by Frank Hinman Jr. *J Sex Med*. 2007 Nov; 4 (6): 1539-43, **Coauthor**
75. Bella AJ, Deyoung LX, Al-Numi M, **Brock GB**. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. *Eur Urol*. 2007 Oct; 52 (4): 990-1005, **Senior Responsible Author**
76. Kovac JR, **Brock GB**. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. *J Sex Med*. 2007 Sep; 4 (5): 1500-8, **Senior Responsible Author**
77. **Brock G**, Carrier S, Casey R, Tarride JE, Elliott S, Dugré H, Rousseau C, D'Angelo P, Defoy I. Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices. *J Sex Med*. 2007 Sep; 4 (5): 1404-13, **Principal Author**
78. Carrier S, **Brock G**, Casey R, Tarride JE, Elliott S, Dugré H, Rousseau C, D'Angelo P, Defoy I. Treatment satisfaction with sildenafil in a Canadian real-life setting. A 6-month prospective observational study of primary care practices. *J Sex Med*. 2007 Sep; 4 (5): 1414-21, **Coauthor**
79. Domes T, De Young L, O'Gorman DB, Gan BS, Bella AJ, **Brock G**. Is there a role for proteomics in Peyronie's disease? *J Sex Med*. 2007 Jul; 4 (4 Pt 1): 867-77, **Senior Responsible Author**
80. Bella AJ, Beasley KA, Obied A, **Brock GB**. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. *Urology*. 2006 Oct; 68 (4): 852-7, **Co-Principal Author**
81. Nicolosi A, Laumann EO, Glasser DB, **Brock G**, King R, Gingell C. Sexual activity, sexual disorders and associated help-seeking behavior among mature adults in five Anglophone countries from the Global Survey of Sexual Attitudes and Behaviors (GSSAB). *J Sex Marital Ther*. 2006 Jul; 32 (4): 331-42, **Collaborator**
82. **Brock G**, Moreira ED Jr, Glasser DB, Gingell C; GSSAB Investigators' Group. Sexual disorders and associated help-seeking behaviors in Canada. *Can J Urol*. 2006 Feb; 13 (1): 2953-61, **Co-Principal Author**
83. Bella AJ, Brant WO, **Brock, GB**. Contemporary intracavernous pharmacotherapy for erectile dysfunction in the aging male. *Aging Health* 2(4): 559-570, 2006, **Co-Principal Author**
84. Goldstein I, Fisher WA, Sand M, Rosen RC, Mollen M, **Brock G**, Karlin G, Pommerville P, Bangerter K, Bandel TJ, Derogatis LR; Vardenafil Study Group. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. *J Sex Med*. 2005 Nov; 2 (6): 819-32, **Collaborator**
85. Fisher WA, Rosen RC, Mollen M, **Brock G**, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. *J Sex Med*. 2005 Sep; 2 (5): 699-708, **Collaborator**
86. Carrier S, **Brock GB**, Pommerville PJ, Shin J, Anglin G, Whitaker S, Beasley CM Jr. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. *J Sex Med*. 2005 Sep; 2 (5): 685-98, **Collaborator**
87. Nehra A, Grantmyre J, Nadel A, Thibonnier M, **Brock G**. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. *J Urol*. 2005 Jun; 173 (6): 2067-71, **Co-Principal Author**
88. Williams BA, Liu C, Deyoung L, **Brock GB**, Sims SM. Regulation of intracellular Ca²⁺ release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. *Am J Physiol Cell Physiol*. 2005 Mar; 288 (3): C650-8, **Collaborator**
89. De Young L, Bella A, Howard J, **Brock G**. Arteriogenic erectile dysfunction alters protein expression within the cavernosal tissue in an animal model. *J Sex Med*. 2005 Mar; 2 (2): 199-206, **Co-Principal Author**
90. Moreira ED Jr, **Brock G**, Glasser DB, Nicolosi A, Laumann EO, Paik A, Wang T, Gingell C; GSSAB Investigators' Group. Help-seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. *Int J Clin Pract*. 2005 Jan; 59 (1): 6-

16, **Collaborator**

91. Lega IC, **Brock GB**, Luke PP. Post-pyeloplasty flank pain treated with laparoscopically-assisted renal autotransplantation. Can J Urol. 2004 Dec; 11 (6): 2459-60, **Collaborator**
92. **Brock GB**. Bicycling: Is It an Independent Risk Factor for Erectile Dysfunction? Current Sexual Health Reports Vol 1, Number 3, October 2004 78-80, **Principal Author**
93. Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, **Brock GB**, Razvi H, Denstedt JD. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004 Oct; 18 (8): 723-30, **Co-Principal Author**
94. Montorsi F, Nathan HP, McCullough A, **Brock GB**, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004 Sep; 172 (3): 1036-41, **Co-Principal Author**
95. De Young L, Yu D, Bateman RM, **Brock GB**. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl. 2004 Sep; 25 (5): 830-6, **Co-Principal Author**
96. Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, **Brock GB**, Tanguay S. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004 Jul; 172 (1): 58-62, **Co-Principal Author**
97. Bella AJ, **Brock GB**. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004 Mar; 23 (2-3): 149-55, **Co-Principal Author**
98. Bella AJ, **Brock GB**. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep. 2003 Dec; 4 (6): 472-8, **Co-Principal Author**
99. Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, Steinhoff G, **Brock G**, Patrick AB, Flax S, Goldfarb B, Palmer BW, Zadra J. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology. 2003 Oct; 62 (4): 614-7, **Collaborator**
100. **Brock G**, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003 Oct; 170 (4 Pt 1): 1278-83, **Co-Principal Author**
101. De Young L, Yu D, Freeman D, **Brock GB**. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res. 2003 Oct; 15 (5): 347-54, **Co-Principal Author**
102. Karkanis T, DeYoung L, **Brock GB**, Sims SM. Ca²⁺-activated Cl⁻ channels in corpus cavernosum smooth muscle: a novel mechanism for control of penile erection. J Appl Physiol. 2003 Jan; 94 (1): 301-13, **Collaborator**
103. **Brock GB**. The PDE5 Inhibitor Tadalafil for the Treatment of Erectile Dysfunction: Integrated Analyses and a Case Report. The American Journal of Urology Review, January/February 2003, Vol 1 No1 (18-24), **Principal Author**
104. **Brock GB**. Tadalafil: A new oral therapy for Erectile Dysfunction. J Sexual and Reproductive Medicine. 2003; 3 (4): 123-7, **Principal Author**
105. Gajewski JB, Carrier S, **Brock GB**, Barkin J. Erectile dysfunction and the Female Partner's Perspective: A Comparison with the Man's Perception. J Sex Repro Med. 2003; 3 (Suppl B): 15B-18B, **Collaborator**
106. Barkin J, Carrier S, Gajewski JB, **Brock GB**. Erectile Function and Male Sexual Satisfaction: A National Survey. J Sex Prod Med Vol 3 Suppl B Winter 2003 10B-14B, **Co-Principal Author**
107. Carrier S, **Brock GB**. Foreword – Canadian Sexual Satisfaction Survey 2003. J Sex Prod Med Vol 3 Suppl B Winter 2003 5B-6B, **Co-Principal Author**
108. **Brock GB**, Carrier S, Gajewski JB, Barkin J. Erectile Dysfunction and the Primary Care Physician's perspective: A Comparison with the Patient's Perception. J Sex Reprod Med Vol 3 Suppl B Winter 2003 19B-22B, **Co-Principal Author**

109. **Brock GB**, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. *J Urol*. 2002 Oct; 168 (4 Pt 1): 1332-6, **Co-Principal Author**
110. Kuan, JK, **Brock GB**. Selective PDE-5 Inhibition Using Tadalafil for the Treatment of Erectile dysfunction. *Expert Opin Investig Drugs*. 2002;11:1-8, **Co-Principal Author**
111. Nicolosi A, Glasser DB, **Brock GB**, Laumann E, Gingell C. Diabetes and Sexual Function in Older Adults: results of an international survey. *Br J Diabetes Vasc Dis*. 2002;2:336-9, **Collaborator**
112. **Brock GB**. Oral Agents: First-Line Therapy for Erectile Dysfunction. *European Urology Supplements* 1 (2002) 13-18, **Principal Author**
113. **Brock G**. Erectile dysfunction: educational forum - I. *Can J Urol*. 2001 Dec; 8 (6): 1416-8, **Principal Author**
114. **Brock G**. Towards optimal ED management: educational forum - II. *Can J Urol*. 2001 Dec; 8 (6): 1419-20, **Principal Author**
115. Berger R, Billups K, **Brock GB**, Broderick GA, Dhabuwala CB, Goldstein I, Hakim LS, Hellstrom W, Honig S, Levine LA, Lue T, Munarriz R, Montague DK, Mulcahy JJ, Nehra A, Rogers ZR, Rosen R, Seftel AD, Shabsigh R, Steers W. Related Articles, Links: Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. *Int J Impot Res*. 2001 Dec; 13 Suppl 5:S39-43, **Collaborator**
116. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, **Brock G**, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. *Int J Impot Res*. 2001 Dec; 13 (6): 317-21, **Collaborator**
117. Merlin SL, **Brock GB**, Begin LR, Hiou Tim FF, Macramalla AN, Seyam RM, Shenouda G, Dion SB. New insights into the role of endothelin-1 in radiation-associated impotence. *Int J Impot Res*. 2001 Apr; 13 (2): 104-9, **Collaborator**
118. **Brock G**, Tu LM, Linet OI. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. *Urology*. 2001 Mar; 57 (3): 536-41, **Co-Principal Author**
119. Kuan, JK, **Brock GB**. The Salvage of the Sildenafil Non-Responder: The Role of Locally Delivered Therapies. *Sexual Dysfunction in Medicine* 2(2):34-39, 2001, **Co-Principal Author**
120. **Brock GB**. The Differential Diagnosis between Andropause and Erectile Dysfunction. *J Sexual and Reproductive Medicine*. 2001; 1 (2): 81-84, **Principal Author**
121. **Brock G**. Oral phentolamine (Vasomax). *Drugs Today (Barc)*, 2000 Feb; 36 (2-3): 121-4, **Principal Author**
122. **Brock G**. Sildenafil citrate (Viagra). *Drugs Today (Barc)*, 2000 Feb; 36 (2-3): 125-34, **Principal Author**
123. Seyam RM, Huynh HT, **Brock GB**. Neuronal and endothelial nitric oxide synthase isoforms: quantification of protein and mRNA in the normal rat penis. *Int J Impot Res*. 1999 Dec; 11 (6): 301-8, **Co-Principal Author**
124. Chan PT, Schondorf R, **Brock GB**. Erectile dysfunction induced by orthopedic trauma managed with a fracture table: a case report and review of the literature. *J Trauma*. 1999 Jul; 47 (1): 183-5, **Co-Principal Author**
125. Wong C, Bégin LR, Reid M, **Brock GB**. Oliguria, an unusual presentation of primary signet ring-cell adenocarcinoma of the urinary bladder: a case report and review of the literature. *J Surg Oncol*. 1999 Jan; 70 (1): 64-7, **Co-Principal Author**
126. Guy L, Bégin LR, Oligny LL, **Brock GB**, Chevalier S, Aprikian AG. Searching for an intrinsic neuroendocrine cell in the kidney. An immunohistochemical study of the fetal, infantile and adult kidney. *Pathol Res Pract*. 1999; 195 (1): 25-30, **Collaborator**
127. Abdel-Gawad M, Huynh H, **Brock GB**. The impact of chronic renal failure on nitric oxide synthase isoforms gene expression in the penis and pelvic ganglia of rats. *J Urol*. 1999; 162 (4): 1473-9, **Co-Principal Author**
128. Abdel-Gawad M, Huynh H, **Brock GB**. Experimental Chronic Renal Failure-Associated Erectile Dysfunction: Molecular Alterations in Nitric Oxide synthase Pathway and IGF-I System. *Mol Urol*. 1999; 3 (2): 117-125, **Co-Principal Author**

129. Obrand DI, Mijangos J, Brassard R, **Brock G**, Steinmetz OK. Ureteropelvic urinary extravasation due to iliac artery aneurysm. *Ann Vasc Surg*. 1998 Sep; 12 (5): 468-70, **Collaborator**
130. Abdelbaky TM, **Brock GB**, Huynh H. Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. *Endocrinology*. 1998 Jul; 139 (7): 3143-7, **Collaborator**
131. Chan PT, Bégin LR, Arnold D, Jacobson SA, Corcos J, **Brock GB**. Priapism secondary to penile metastasis: a report of two cases and a review of the literature. *J Surg Oncol*. 1998 May; 68 (1): 51-9, **Co-Principal Author**
132. Huynh H, Seyam RM, **Brock GB**. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor 1 (IGF-1), IGF-1 receptor and increased IGF binding protein 3. *Cancer Res*. 1998 Jan; 58 (2): 215-8, **Co-Principal Author**
133. Huynh H, Seyam RM, **Brock GB**. Regulation of penile insulin-like growth factor system expression by DHT: relation to erectile dysfunction. *Molec. Urol*. 2:23, 1998, **Co-Principal Author**
134. von Heyden B, Anthony JP, **Brock GB**, Kaula N, Tanagho EA. The latissimus dorsi bladder myoplasty to assist detrusor function. *Urol Res*. 1998; 26 (3): 215-21, **Collaborator**
135. Seyam RM, Bégin LR, Tu LM, Dion SB, Merlin SL, **Brock GB**. Evaluation of a no-needle penile injector: a preliminary study evaluating tissue penetration and its hemodynamic consequences in the rat. *Urology*. 1997 Dec; 50 (6): 994-8, **Co-Principal Author**
136. **Brock G**, Hsu GL, Nunes L, Von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. *J Urol*. 1997 Jan; 157 (1): 276-81, **Co-Principal Author**
137. Karakiewicz PI, Bazinet M, Zvara P, Bégin LR, **Brock GB**. Blunt cavernous nerve injury: A new animal model mimicking postradical prostatectomy neurogenic impotence. *Urol Oncol*. 1996 Sep; 2 (5): 158-62, **Co-Principal Author**
138. Plante M, Corcos J, Gregoire I, Belanger MF, **Brock G**, Rossingol M. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. *Urology*. 1996 Mar; 47 (3): 326-8, **Collaborator**
139. Zvara P, Spiess PE, Merlin SL, Bégin LR, **Brock GB**. Neurogenic erectile dysfunction: the course of nicotinamide adenine dinucleotide phosphate diaphorase-positive nerve fibers on the surface of the prostate. *Urology*. 1996 Jan; 47 (1): 146-51, **Co-Principal Author**
140. Spiess PE, Dion SB, Zvara P, Merlin SL, Chan PT, **Brock GB**. 7-Nitroindazole: a selective inhibitor of penile erection: an in vivo study in a rat animal model. *Urology*. 1996 Jan; 47 (1): 93-6, **Co-Principal Author**
141. Seyam RM, Merlin SL, **Brock GB**. Erectile dysfunction following definitive treatment for prostate cancer. *Canadian Journal of Urology*; 3(1) 89-95, 1996, **Co-Principal Author**
142. von Heyden B, **Brock GB**, Martinez-Piñeiro L, Lue TF. Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long-term use. *Eur Urol*. 1996; 30 (4): 502-5, **Collaborator**
143. Zvara P, Sioufi R, Schipper HM, Bégin LR, **Brock GB**. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. *Int J Impot Res*. 1995 Dec; 7 (4): 209-19, **Co-Principal Author**
144. Lue TF, Gleason CA, **Brock GB**, Carroll PR, Tanagho EA. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. *J Urol*. 1995 Oct; 154 (4): 1426-8, **Collaborator**
145. Martínez-Piñeiro L, Dahiya R, **Brock GB**, Hsu GL, von Heyden B, Lue TF. Chronic penile denervation in the rat: effect on cavernous tissue morphology and function. *Int J Impot Res*. 1995 Sep; 7 (3): 165-74, **Collaborator**
146. von Heyden B, Riemer RK, Nunes L, **Brock GB**, Lue TF, Tanagho EA. Response of guinea pig smooth and striated urethral sphincter to cromakalim, prazosin, nifedipine, nitroprusside, and electrical stimulation. *Neurourol Urodyn*. 1995; 14 (2): 153-68, **Collaborator**
147. Wolf JS Jr, **Brock GB**, Gleason CA, Zvara P, Lue TF, Carroll PR. Laparoscopically implantable nerve-stimulating electrode (LINSE):

- application to the cavernous nerve in acute and chronic canine models. J Endourol. 1994 Oct; 8 (5): 375-8, **Collaborator**
148. Hsu GL, **Brock G**, von Heyden B, Nunes L, Lue TF, Tanagho EA. The distribution of elastic fibrous elements within the human penis. Br J Urol. 1994 May; 73 (5): 566-71, **Collaborator**
149. Hsu GL, **Brock G**, Martínez-Piñeiro L, von Heyden B, Lue TF, Tanagho EA. Anatomy and strength of the tunica albuginea: its relevance to penile prosthesis extrusion. J Urol. 1994 May; 151 (5): 1205-8, **Collaborator**
150. von Heyden B, Anthony JP, Kaula N, **Brock GB**, Jakse G, Tanagho EA. The latissimus dorsi muscle for detrusor assistance: functional recovery after nerve division and repair. J Urol. 1994 Apr; 151 (4): 1081-7, **Collaborator**
151. Zvara P, **Brock GB**. Peyronie's disease: developments in diagnosis and treatment. Can J Urol. 1994 Jan; 1 (1): 5-12, **Co-Principal Author**
152. Martínez-Piñeiro L, **Brock G**, Trigo-Rocha F, Hsu GL, Lue TF, Tanagho EA. Rat model for the study of penile erection: pharmacologic and electrical-stimulation parameters. Eur Urol. 1994; 25 (1): 62-70, **Collaborator**
153. von Heyden B, Donatucci CF, Marshall GA, **Brock GB**, Lue TF. A prostaglandin E1 dose-response study in man. J Urol. 1993 Dec; 150 (6): 1825-8, **Collaborator**
154. Carrier S, **Brock G**, Kour NW, Lue TF. Pathophysiology of erectile dysfunction. Urology. 1993 Oct; 42 (4): 468-81, **Collaborator**
155. **Brock G**, Nunes L, von Heyden B, Martinez-Piñeiro L, Hsu GL, Lue TF. Can a venous patch graft be a substitute for the tunica albuginea of the penis? J Urol. 1993 Oct; 150 (4): 1306-9, **Co-Principal Author**
156. **Brock G**, Nunes L, Padma-Nathan H, Boyd S, Lue TF. Nitric oxide synthase: a new diagnostic tool for neurogenic impotence. Urology. 1993 Oct; 42 (4): 412-7, **Co-Principal Author**
157. **Brock G**, Breza J, Lue TF, Tanagho EA. High flow priapism: a spectrum of disease. J Urol. 1993 Sep; 150 (3): 968-71, **Co-Principal Author**
158. **Brock G**, Breza J, Lue TF. Intracavernous sodium nitroprusside: inappropriate impotence treatment. J Urol. 1993 Sep; 150 (3): 864-7, **Co-Principal Author**
159. **Brock G**, Kadioglu A, Lue TF. Peyronie's disease: a modified treatment. Urology. 1993 Sep; 42 (3): 300-4, **Co-Principal Author**
160. **Brock GB**, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf. 1993 Jun; 8 (6): 414-26, **Co-Principal Author**
161. Hsu GL, **Brock GB**, Trigo-Rocha F, Martinez-Piñeiro L, Lue TF. Combined cavernous compression device and arteriovenous-cavernous fistula: a chronic canine model. J Urol. 1993 Jun; 149 (6): 1564-7, **Co-Principal Author**
162. Dahiya R, Trigo-Rocha F, **Brock G**, Narayan P, Lue TF. Sodium nitroprusside and neurostimulation cause increased levels of cyclic guanosine monophosphate and not cyclic adenosine monophosphate during canine penile erection. Biochem Mol Biol Int. 1993 Jan; 29 (1): 167-73, **Collaborator**
163. **Brock GB**, Lue TF. Sexual dysfunction after radical pelvic surgery. Trends in Urology 3:4, 1992, **Co-Principal Author**
164. **Brock GB**, Lue TF. Impotence: A patient's goal directed approach. Urology Monograph. 99-110, 1992, **Co-Principal Author**
165. Hsu GL, **Brock GB**, Martinez-Pineiro L, von Heyden B, Lue TF, Tanagho EA. The three-dimensional structure of the tunica albuginea: anatomical and ultrastructural levels. Int J Impot Res. 1992;4:117-129, **Co-Principal Author**
166. King M, **Brock G**, Lundell C. Clearance of mucus by simulated cough. J Appl Physiol Jun, 1985 Jun; 58 (6): 1776-82, **Coauthor**

Accepted / In Press

1. Ortac M, Brock GE. Pharmacologic and surgical therapies for male cancer survivors. Translational Andrology and Urology, 2014 Nov 1, **Senior Responsible Author**
2. **Brock G**. Effect of Tadalafil Once Daily (OaD) on Penile Length-Loss and Morning Erections in Patients Post Bilateral Nerve-

Sparing Radical Prostatectomy (nsRP): Results from a Randomized Controlled Trial. Urology, 2014 Nov, **Principal Author**

3. Garcia F, Violette P, **Brock G**, Pautler S. Predictive factors for return of potency in Robotic Radical Prostatectomy: Case series from a single centre. International Journal of Impotence Research: The Journal of Sexual Medicine, 2014 Jun, **Senior Responsible Author**
4. **Brock G**, Montorsi F, Costa P, Shah N, Martinez-Jabaloyas JM Hammerer P, Ludovico GM, Lee JC, Hennes C, Hamidi K, Rossi A, Büttner H, Mulhall J. Effect of Tadalafil Once Daily (OaD) on Penile Length-Loss and Morning Erections in Patients Post Bilateral Nerve-Sparing Radical Prostatectomy (nsRP): Results from a Randomized Controlled Trial. 2012 Jul 1, **Senior Responsible Author**
5. Chung E, Bella A, Lee JC, Elliot SL, Carrier S, **Brock GB**. Urological Association Practice Guideline on premature ejaculation. Canadian Urological Association Journal (accepted), **Coauthor**
6. Auld RB, **Brock GB**. Sexuality and Erectile Dysfunction: results of a national survey. Canadian Male Sexual Health Council. J. Sexual and Repro. Med (accepted), **Co-Principal Author**

Submitted

1. Garcia F, Violette PD, Matsumoto ED, **Brock GB**, Pautler SE. Nerve-sparing Prostatectomy Benefits Men with Poor Pre-operative Erectile Dysfunction. 2013 Nov, **Coauthor**

Book Chapter / Review Article

Published

1. Bella AJ, **Brock GB**. Tadalafil: Long acting PDE5i; 2008. Textbook of erectile dysfunction, **Co-Principal Author**
2. **Brock GB**, Bella AJ. The contemporary role of penile duplex scanning in sexual dysfunction; 2008. Carson et al editors, Textbook of Erectile Dysfunction, **Senior Responsible Author**
3. Ray AA, **Brock GB**. Erectile Dysfunction; 2005. In: Conn's Current Therapy: Medical Therapy 2005, Section 10; Pg 818. Elsevier Saunders-Philadelphia, Pennsylvania (USA). 2005, **Co-Principal Author**
4. Fazio L, **Brock G**. Erectile dysfunction: management update. CMAJ. 170; 2004. p.1429-37, **Co-Principal Author**
5. Kaun JK, **Brock GB**. Pharmacotherapy and External Devices; 2004. Atlas of Male Sexual Dysfunction. 2004, **Co-Principal Author**
6. **Brock GB**. MUSE and Intracavernosal Therapies; 2004. Male and Female Sexual Dysfunction, Seftel, Allen D, Editor. 2004. 121-128, **Principal Author**
7. **Brock GB**. Chapter: Erectile Dysfunction in the Aging Male; 2003. Mechanisms in Andropause. Chapter 10, 2003. 159-172, **Principal Author**
8. **Brock GB**, Bochinski D. Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. Curr Opin Urol. 11; 2001. p.625-30, **Co-Principal Author**
9. Pautler SE, **Brock GB**. Priapism. From Priapus to the present time. Urol Clin North Am. 28; 2001. p.391-403, **Co-Principal Author**
10. Bochinski D, **Brock GB**. Medications Affecting Erectile Function. Male Sexual Function-A Guide to Clinical Management; 2001. Mulcahy, JJ, Editor. The Humana Press Inc. 2001, **Co-Principal Author**
11. Beasley K. DeYoung L, **Brock GB**. Current Status to Standardized Questionnaires in the Measurement of Erectile Dysfunction. Curr Urol Rep. 1; 2000. p.285-90, **Co-Principal Author**
12. Krane R, **Brock G**, Eardley I, Fourcroy J, Giuliano F, Hutter A, Teloken C, Vickers M. Oral Non-Endocrine Treatment Committee; 1999. International Consultation on Erectile Dysfunction Paris July, 1999, **Co-Principal Author**

13. **Brock GB.** Nocturnal Penile Tumescence Testing; 1999. In Clinical Urology ed. Hellstrom, **Principal Author**
14. Chan P, **Brock GB.** Surg induced sexual dysfunction; 1997. Baillieres Clinical Psychiatry 3:1, 1997, **Co-Principal Author**
15. **Brock GB,** Zvara P. Les vessie neurogenes de L'adulte; 1996. J Corcos and E Shick editors, Masson, Paris, 1996, **Co-Principal Author**
16. **Brock GB.** Priapism; 1995. Current Urologic Therapy, Seidmon E.J. Hanno P.M. editors. 3rd edition. Philadelphia: W.B. Saunders 1995, **Principal Author**
17. **Brock GB,** Lue TF. Penile Venous Surgery in Reconstructive Urology; 1995. J. McAninch, editor. W.B. Saunders, Orlando 1995, **Co-Principal Author**
18. **Brock GB,** Lue TF. Traumatic Priapism in Reconstructive Urology; 1995. J. McAninch, editor. W.B. Saunders, Orlando 1995, **Co-Principal Author**

Accepted / In Press

1. **Brock, G.** Biomaterials: Penile Prosthetics; 2009. Atala and Denstedt, Biomaterials in Urology. 1 edition, Jun 5 2009, **Senior Responsible Author**
2. **Brock GB,** Lim KB. Treatment of Sexual dysfunction in the elderly; 2005. Lunenfeld, Morales & Gooren: Textbook of Health in Aging Men, Second Edition, **Co-Principal Author**

Invited Editorial

Published

1. **Brock G.** Editorial comment. Urology. 2009 Oct; 74 (4): 799;,, **Principal Author**
2. **Brock GB.** Editorial comment on: Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol. 2009 Jan; 57 (3): 528-9, **Editor**

Letters to Editor

Published

1. **Brock GB.** Editorial comment on: Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol. 2009 Jan, 57. (3): p.528-9, **Principal Author**

Non-Peer Reviewed Publications

Invited Editorial

Published

1. Valiquette L, Montorsi F, Hellstrom WJ, Giuliano F, Homering M, Taylor T, Eardley I; Vardenafil Study Group. Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis. Can J Urol. 2005 Jun; 12 (3): 2687-98;,, **Reviewer**
2. **Brock G.** Who should be treating erectile dysfunction? Nat Clin Pract Urol. 2005 May; 2 (5): 205, **Principal Author**

3. **Brock GB.** Editorial: Evidence Belies the Myths and Draws a Reassuring Message. Andropause and Testosterone Therapy: Geriatrics & Aging Supplement: Nov/Dec 2003 Vol. 6, No.10, page 3, **Principal Author**
4. **Brock G.** Erectile function of bike patrol officers. J Androl. 2002 Nov; 23 (6): 758-9;; **Principal Author**

ABSTRACTS

Abstracts Published

Peer Reviewed

Published

1. **Brock G,** Kovac J. An analysis of dermal, pericardial and small intestinal submucosal grafts in the surgical management of Peyronie's Disease; 2005. European Society for Sexual Medicine (ESSM) Copenhagen Meeting December 4-7, 2005. **Senior Responsible Author**
2. **Brock G,** Gan BS, Lim KB, DeYoung L, Bella A. Use of SELDI to determine whether Peyronie's Disease Protein Expression can predict progression; 2005. European Society for Sexual Medicine (ESSM) Copenhagen Meeting December 4-7, 2005. **Senior Responsible Author**
3. Bella A, Sener A, Foell K, **Brock G.** Atypical peyronie's disease: an undiagnosed cause of erectile dysfunction; 2005. Sexual Medicine Society of North America, Fall Meeting November 17-20, 2005. **Senior Responsible Author**
4. **Brock G,** Bella A, Gan BS, De Young L. Use of seldi to determine whether peyronie's disease protein expression can predict progression; 2005. Sexual Medicine Society of North America, Fall Meeting November 17-20, 2005. **Senior Responsible Author**
5. De Young L, Bella A, Gan BS, **Brock G.** The pathogenesis of peyronie's disease: a state of altered wound healing; 2005. Sexual Medicine Society of North America, Fall Meeting November 17-20, 2005. **Senior Responsible Author**
6. Fisher W, Rosen R, Mollen M, **Brock G,** Karlin G, Pommerville P, Goldstein I, Bangerter K, Taylor T, Derogatis L. A novel methodology for comprehensively assessing the multidimensional impact of erectile dysfunction on couples; 2005. World Congress of Sexology. Montreal July 10-15, 2005. **Coauthor**
7. Fazio L, **Brock G.** Defining Patient characteristics of Sildenafil Responsiveness. Can J Urol. 59th Annual Meeting of the Canadian Urology Association.; 2004. **Co-Principal Author**
8. Morales A, Lee J, Guertin B, **Brock G,** Segerson T, and the Vardenafil Study Team. Sustained Efficacy and Tolerability of Levitra®-Vardenafil-Over Two Years in Men with Erectile Dysfunction. Can J Urol. 59th Annual Meeting of the Canadian Urology Association.; 2004. **Collaborator**
9. **Brock G,** Chan M. Klotz S. etc. Randomized Trial of Tadalafil in Canadian Men with Erectile Dysfunction Following bilateral Nerve-Sparing Radical Retropubic Prostatectomy. Can J Urol. 59th Annual Meeting of the Canadian Urology Association.; 2004. **Co-Principal Author**
10. **Brock G,** Laumann EO, Glasser DB, et al. Sexual Attitudes and Beliefs of Middle-aged and Older Adults in Non-European Westernized Countries: Data from the Global Study of Sexual Attitudes and Behaviors-GSSAB. Can J Urol. 59th Annual Meeting of the Canadian Urology Association.; 2004. **Co-Principal Author**
11. Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, **Brock GB,** et al. A Double-Blinded Prospective Randomized Controlled Trial Assessing the Safety and Efficacy of Intravesical Agents For Ureteral Stent Symptoms Following ExtraCorporeal Shock Wave Lithotripsy; 2004. 59th Annual Meeting of the Canadian Urology Association. Can J Urol. 2004 June;11(3) Podium no.47. **Co-**

Principal Author

12. **Brock GB**, Laumann EO, Glasser DB, et al. Prevalence and Correlates of Sexual Problems Among Mature Men and Women in Western Non-European and Central and South American Regions: The Global Study of Sexual Attitudes and Behaviors; 2004. American Urology Association – San Francisco – May 8-13/04 no.149. J Urol. 2004 May 8;171(4 Suppl). **Co-Principal Author**
13. DeYoung L, Batemen R, **Brock GB**. Oxidative Stress and Antioxidant Therapy: Their Potential For Salvage Therapy in Diabetes Associated Erectile Dysfunction; 2004. American Urology Association – San Francisco – May 8-13/04 #1424. J Urol. 2004 May 11;171(4 Suppl). **Co-Principal Author**
14. Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, **Brock GB**, et al. A Double Blinded Prospective Randomized Controlled Trial Assessing the Safety and Efficacy of Intravesical Agents for Ureteral Stent Symptoms Following ExtraCorporeal Shock Wave Lithotripsy; 2004. American Urology Association – San Francisco – May 8-13/04 #1884. J Urol. 2004 May 12;171(4 Suppl). **Co-Principal Author**
15. Beasley K, Obied A, **Brock GB**. Minimally Invasive Peyronie's Repair: Initial Experiences with a New Technique; 2004. The American Urological Association Meeting, Anaheim California, 04/01. **Senior Responsible Author**
16. Bella AJ, Beasley KA, **Brock GB**. Minimally Invasive Peyronie's Repair: Initial Experiences with a New Technique. J Sex Med. Moderated Poster at International Society for Sexual and Impotence Research.; 2004. p. MP86. **Co-Principal Author**
17. Moreira E, Laumann EO, Glasser DB, Nicolosi A, Paik A, Wang T, **Brock G**, et al. Help-seeking Behavior for Sexual Problems Among Men and Women in The Global Study of Sexual Attitudes and Behaviors. J Sex Med. Moderated Poster at International Society for Sexual and Impotence Research.; 2004. p. MP113. **Co-Principal Author**
18. **Brock G**, DeYoung L. Combined VEGF and antioxidants act synergistically to restore erectile function in diabetic rats. J Sex Med. Moderated Poster at International Society for Sexual and Impotence Research.; 2004. p. MP119. **Co-Principal Author**
19. **Brock GB**, Porst H, Stief CG et al. Influence of prior Sildenafil use of the efficacy of Vardenafil in men with erectile dysfunction: retrospective analysis of a two year study.; 2004. American Urology Association, May 2004, San Francisco, Ca. J Urology 2004;171(4), supplement. **Senior Responsible Author**
20. Zvara P, Spiess PE, Tripp B, Merlin S, Bigin LR, **Brock GB**. Minimally invasive diagnostic technique for neurogenic impotence. J Urol.; 1995. p. 331A. **Co-Principal Author**
21. Zvara P, Spiess PE, Merlin SL, Bigin LR, Corcos J, **Brock GB**. Topography of the nitric oxide releasing nerve fibres responsible for erection. J Urol.; 1995. p. 507A. **Co-Principal Author**
22. von Heyden B, **Brock GB**, Lue TF. No Sin1 toxicity found in monkeys following long term intracavernous administration. J Urol.; 1995. p. 440A. **Collaborator**
23. von Heyden B, Anthony JP, **Brock GB**, Tanagho EA. Kann Skelettmuskel den Detrusor ersetzen?; 1994. Der Urologe A, Suppl. 1/94: S 99, 1994. **Collaborator**
24. von Heyden B, **Brock GB**, Lue TF, Tanagho EA. In vitro Untersuchung zur Relaxation und Rolle der glatten und quergestreiften Muskulatur des urethralen Sphinkters; 1994. Der Urologe A, Suppl. 1/94: 39, 1994. **Collaborator**
25. **Brock GB**, Lue TF. Nitric oxide synthase: a new diagnostic tool for neurogenic impotence; 1993. AUA, Western Section, Palm Desert. November 17, 1993. **Senior Responsible Author**
26. von Heyden B, **Brock GB**. Latismus myoplasty: a new treatment.; 1993. AUA, Western Section, Palm Desert. Nov. 1993. **Senior Responsible Author**
27. **Brock GB**, Nunes L, Nathan P, Lue TF. Nitric oxide synthase: a new diagnostic test for neurogenic impotence; 1993. Quebec Urologic Association Annual Meeting. Montreal (Quebec), November 1993. **Senior Responsible Author**
28. Hsu GL, **Brock GB**, Trigo-Rocha F, Martinez-Pineiro L, Lue TF, Tanagho EA. The three-dimensional structure of the tunica albuginea: anatomical and ultrastructural levels; 1992. AUA, Western Section Annual Meeting, Maui, October 25, 1992.

Senior Responsible Author

29. Hsu GL, **Brock GB**, Trigo-Rocha F, Martinez-Pineiro L, Lue TF, Tanagho EA. Combined cavernous compression device and arteriovenous?cavernous fistula: a chronic canine model; 1992. AUA, Western Section Annual Meeting, Maui, October 25, 1992. **Senior Responsible Author**
30. **Brock GB**, Martinez-Pineiro L, Hsu GL, von Heyden B, Lue TF. Use of penile venous patch-graft for Peyronie's disease in a rat model; 1992. AUA, Western Section Annual Meeting, Maui, October 25, 1992. **Senior Responsible Author**
31. Von Heyden B, Marshall GA, Donatucci CF, **Brock GB**, Lue TF. Prostaglandin E-1 pharmacotherapy of impotence: a dose-response study in man; 1992. AUA, Western Section Annual Meeting, Maui, October 25, 1992. **Senior Responsible Author**
32. Hsu GL, **Brock GB**, Martinez-Pineiro L, von Heyden B, Lue TF, Tanagho EA. Anatomy and strength of the tunica albuginea: its relevance to penile prosthesis extrusion; 1992. 5th World Meeting on Impotence, Milan (Italy), September 13-17, 1992. **Senior Responsible Author**
33. Hsu GL, **Brock GB**, Trigo-Rocha F, Martinez-Pineiro L, Lue TF. Combined cavernous compression device and arteriovenous-cavernous fistula: a chronic canine model; 1992. 5th World Meeting on Impotence, Milan (Italy), September 13-17, 1992. **Senior Responsible Author**
34. Martinez-Pineiro L, **Brock GB**, Hsu GL, von Heyden B, Lue TF, Tanagho EA. Efectos a largo plazo de la denervation del pene sobre la morfologia y function del tejido cavernoso; 1992. Spanish Urological Annual Meeting, Madrid, September 4-9, 1992. **Senior Responsible Author**
35. Hsu GL, **Brock GB**, Martinez-Pineiro L, von Heyden B, Lue TF, Tanagho EA. The three-dimensional structure of the tunica albuginea: anatomical and ultrastructural levels; 1992. 5th World Meeting on Impotence, Milan (Italy), September 13-17, 1992. **Senior Responsible Author**
36. Martinez-Pineiro L, Trigo-Rocha F, Hsu GL, **Brock GB**, Lue TF, Tanagho EA. A new rat model for the study of penile erection: electrical parameters and erection response; 1992. P154 European Urology, Genoa (Italy), July 22-25, 1992. **Senior Responsible Author**
37. von Heyden B, Donatucci CF, **Brock GB**, Lue TF. Intracavernous pharmacotherapy: how much with drug?; 1992. AUA, Western Section Annual Meeting, Maui, October 25, 1992. **Senior Responsible Author**
38. **Brock GB**, Trigo-Rocha F, Martinez-Pineiro L, Hsu GL, Donatucci CF, Hohenfellner M and Lue TF. The role of the intracellular second messengers in cavernous smooth muscle relaxation.; 1992. Canadian Urological Association Annual Meeting, Winnipeg (Manitoba), 1992. **Senior Responsible Author**
39. **Brock GB**, Pike J, Kiruluta G. The effect of sympathectomy on voiding function a mouse model; 1992. Quebec Association of Urology Annual Meeting, Montreal, 1990. **Senior Responsible Author**
40. **Brock GB**, Kodiglu A, Trigo-Rocha F, Lue TF. Peyronie's disease: A modified approach to treatment; 1992. Canadian Urological Association Annual Meeting. Winnipeg (Manitoba), 1992. **Senior Responsible Author**
41. **Brock GB**, Trigo-Rocha F, Martinez-Pineiro L, Hsu GL, Lue TF, Tanagho EA. Sodium nitroprusside: a new approach for the treatment of penile erectile dysfunction; 1992. Canadian Urological Association Annual Meeting. Winnipeg (Manitoba), 1992. **Senior Responsible Author**
42. Martinez-Pineiro L, Trigo-Rocha F, Hsu GL, **Brock GB**, Lue TF, Tanagho EA. A new rat model for the study of penile erection: electrical stimulation parameters and erection response; 1992. European Urological Association Annual Meeting. July, 1992. **Senior Responsible Author**
43. **Brock GB**, Pike J, Kiruluta G. The use of ultrasound to define bladder wall thickness in children; 1990. Quebec Association of Urology Annual Meeting, Montreal, 1990. **Senior Responsible Author**
44. **Brock GB**, Fauzy M, Elhilali M. Use of an infuse aid for delivery of intra cavitory chemotherapy in upper tract TCC.; 1989. Canadian Urological Association Annual Meeting, Quebec City, 1989. **Senior Responsible Author**

PRESENTATIONS

Invited Lectures

1. **Invited Lecturer**, South African Urological Society, South Africa, Teaching prosthetics and ED rehabilitation, 2014 Sep, Presenters: **Brock G**
2. **Invited Lecturer**, Australian Urological Association, Australia, Erectile dysfunction and men's health, 2014 Mar, Presenters: **Brock G**
3. **Invited Lecturer**, University of Toronto Men's Health Summit, Toronto, Ontario, Canada, CVD and ED, 2014 Jan, Presenters: **Brock G**
4. **Invited Lecturer**, 2013 Evidence-Based Management of the Diabetes Epidemic, McMaster University, Hamilton, Ontario, Canada, Clinical pearls for optimizing sexual function in men with type 2 diabetes, 2013 Nov 13, Presenters: **Brock G**
5. **Invited Lecturer**, Sexual Medicine Society of North America, New Orleans, Louisiana, United States, Erectile dysfunction and Peyronie's disease, 2013 Nov, Presenters: **Brock G**
6. **Invited Lecturer**, Canadian Urological Association, GP Update Series, Ontario, Canada, Management of the hypogonadal male, 2013 Jun, Presenters: **Brock G**
7. **Invited Lecturer**, Canadian Urological Association, GP Update Series, Ontario, Canada, Treatment of erectile dysfunction 2013, 2013 Jun, Presenters: **Brock G**
8. **Invited Lecturer**, Canadian Cardiovascular Research Network, Toronto, Ontario, Canada, ED and CVD: What is the connection? 2013 Jun, Presenters: **Brock G**
9. **Invited Lecturer**, American Urological Association, San Diego, California, United States, Penile rehabilitation course, 2013 May, Presenters: **Brock G**
10. **Invited Lecturer**, American Urological Society, San Diego, California, United States, Endocrine forum: Peyronie's disease is best managed with surgery, 2013 May, Presenters: **Brock G**
11. **Invited Lecturer**, American Urological Society, San Diego, California, United States, Society of University Urologists: The Canadian Residency Programs in Urology - Changes for 2013, 2013 May, Presenters: **Brock G**
12. **Invited Lecturer**, South African Urology Association, Sun City, South Africa, Evolving therapies for ED and priapism, 2012 Nov, Presenters: **Brock G**
13. **Invited Lecturer**, Chinese Andrology Society Meeting, Chicago, Illinois, United States, Preserving penile length after penile prosthetic surgery, 2012 Aug, Presenters: **Brock G**
14. **Invited Lecturer**, SMSNA-ISSM World Meeting 2012, Chicago, Illinois, United States, Slate Debate - Is there a role for testosterone in Peyronie's disease? 2012 Aug, Presenters: **Brock G**
15. **Invited Lecturer**, SMSNA-ISSM World Meeting 2012, Chicago, Illinois, United States, Chair: Video surgical session, 2012 Aug, Presenters: **Brock G**
16. **Visiting Professor**, University of British Columbia, British Columbia, Canada, 2011 Sep, Presenters: **Brock G**
17. **Visiting Professor**, University of Alberta, Edmonton, Alberta, Canada, 2011 Sep, Presenters: **Brock G**
18. **Invited Lecturer**, Men's Health Forum, Vancouver, British Columbia, Canada, 2011 Sep, Presenters: **Brock G**
19. **Invited Lecturer**, Turkish Andrology Society, Turkey, Stem cell research update - PDE5i's in Urology, Penile Rehabilitation

following prostatectomy. 2011 Jun, Presenters: **Brock GB**.

20. **Invited Lecturer**, American Urological Association. Washington, District of Columbia, United States, Take home messages in sexual dysfunction. 2011 May, Presenters: **Brock GB**.
21. **Invited Lecturer**, Jackson Hole, Wyoming, United States, Urology - Critique Panel. 2011 Feb, Presenters: **Brock GB**.
22. **Invited Lecturer**, South African Urology Association. South Africa, Penile rehabilitation. 2010 Nov, Presenters: **Brock GB**.
23. **Invited Lecturer**, ISSM. Soeul, Korea, Democratic People's Republic Of, Peyronie's disease surgical management. 2010 Sep, Presenters: **Brock GB**.
24. **Invited Lecturer**, American Urological Association, San Francisco, California, United States, Endocrinology Forum: The role of evolving pharmathereapeutics in premature ejaculation, 2010 May, Presenters: **Brock GB**
25. **Invited Lecturer**, American Urological Association, San Francisco, California, United States, Penile rehabilitation post-graduate course, 2010 May, Presenters: **Brock GB**
26. **Invited Lecturer**, Hong Kong Andrology Society, Hong Kong, China, PDE5i the role of daily therapy, 2009 May, Presenters: **Brock GB**
27. **Invited Lecturer**, London, Ontario, Canada, Sex in the Elderly - Geriatric Update, 2009 May, Presenters: **Brock GB**
28. **Visiting Professor**, Hong Kong Andrology Association, HK, Hong Kong, Update of evolving research in ED, 2009 May, Presenters: Brock
29. **Invited Lecturer**, Canadian Geriatric Society, Toronto, Ontario, Canada, Update on T and Prostate Disease, 2009 Apr, Presenters: Brock
30. **Invited Lecturer**, Canadian Geriatric Society, Toronto, Ontario, Canada, Testosterone Update, 2009 Apr, Presenters: **Brock GB**
31. **Keynote Speaker**, American Urological Association, Chicago, Illinois, United States, Graft repair of Peyronie's Disease, 2009 Apr, Presenters: **Brock GB**
32. **Keynote Speaker**, American Urological Association, Chicago, Illinois, United States, SMSNA Debate: Is testosterone safe in men with prostate cancer? 2009 Apr, Presenters: **Brock GB**
33. **Keynote Speaker**, AUA, Chicago, Illinois, United States, PD, 2009 Apr, Presenters: Brock
34. **Invited Lecturer**, SMSNA, United States, Use of T in Men with Prostate Cancer : Plenary Debate, 2009 Apr
35. **Invited Lecturer**, ISSM, Brussels, Belgium, Sexual Medicine, 2008 Nov, Presenters: **Brock GB**
36. **Invited Lecturer**, International Society for the Study of Sexual Medicine, Brussels, Belgium, Evolving understanding of ED, 2008 Nov, Presenters: Brock
37. **Invited Lecturer**, SMSNA, Canada, Is Bicycling a safe activity for Sexual Function, 2008 Nov, Presenters: Brock
38. **Visiting Professor**, Japanese Andrology Association, Japan, 2008 Sep, Presenters: **Brock GB**
39. **Invited Lecturer**, SMSNA at the AUA, Florida, United States, Peyronie's disease approaches , minimal Tx, 2008 May, Presenters: **Gerald Brock**
40. **Invited Lecturer**, CSSAM Canadian Society for the Study of the Aging Male, Montreal, Quebec, Canada, The role of testosterone on prostate cancer, 2008 Apr, Presenters: **gerald Brock**
41. **Invited Lecturer**, Canadian Cancer Society, St John's, Canada, ED following prostate cancer, 2008 Apr, Presenters: **Gerald Brock**
42. **Visiting Professor**, University of Alberta, Edmonton, Alberta, Canada, ED and dosing advances, 2008 Apr, Presenters: **Gerald Brock**

43. **Visiting Professor**, Winnipeg, Manitoba, Canada, ED and the diabetic-Endocrinologists
ED and prostate cancer/Peyronie's disease-Urologists, 2008 Apr, Presenters: **Gerald Brock**
44. **Invited Lecturer**, London, Ontario, Canada, Prostate cancer and beyond, 2008 Apr, Presenters: **Brock GB**
45. **Invited Lecturer**, Prostate Cancer Support Group of London, London, Ontario, Canada, Ask the expert about prostate cancer -
erectile dysfunction, 2008 Apr, Presenters: **Brock GB**
46. **Invited Lecturer**, ISSAM International Society for the Study fo the Aging Male, Tampa, Florida, United States, The role of
Testosterone in Erection, 2008 Feb, Presenters: **Gerald Brock**
47. **Invited Lecturer**, Montreal, Quebec, Canada, Aging Male Conference, 2008 Feb, Presenters: **Brock GB**
48. **Invited Lecturer**, Sexual Medicine Society of North America, Chicago, Illinois, United States, Peyronie's disease treatment, 2007
Dec, Presenters: **Gerald Brock**
49. **Keynote Speaker**, European Society of Sexual Medicine, Portugal, Erectile dysfunction Update using novel dosing regimes, 2007
Nov, Presenters: **Gerald Brock**
50. **Visiting Professor**, University of Thessaloniki, Greece, Greece, Peyronie's disease
Update on ED
Is daily dosing an advance, 2007 Oct, Attendees: 100, Presenters: **Gerald Brock**
51. **Invited Lecturer**, University of Toronto, Updates, Toronto, Ontario, Canada, penile rehabilitation, 2007 Oct, Presenters: **Gerald
Brock**, Neil Fleschner
52. **Invited Lecturer**, Japanese urological Association, Tokyo, Japan, Update on the role of PDE5i's in ED, 2007 Sep, Presenters:
Gerald Brock
53. **Moderator**, International Urological Summit, Saigon, Viet Nam, Chair, 4th Annual International Urological Summit, 2007 Sep,
Presenters: **Brock GB**
54. **Invited Lecturer**, Taiwan Urological Association, Taipei, Taiwan, Province Of China, 2007 Aug, Presenters: **Brock GB**
55. **Invited Lecturer**, British Urological Association, Glasgow, Scotland, United Kingdom, 2007 Jul, Presenters: **Brock GB**
56. **Invited Lecturer**, University of Patras, Greece, 2007 Jun, Presenters: **Brock GB**
57. **Invited Lecturer**, University of Toronto, Canada, Grand Rounds U of T, 2007 Feb, Presenters: **Gerald Brock**
58. **Moderator**, ESSM, Vienna, Austria, Chair, ED Symposium, 2006 Dec, Presenters: **Brock GB**
59. **Invited Lecturer**, SMSNA, Las Vegas, Nevada, United States, Debate Speaker: The role of penile rehab in prostate cancer
patients, 2006 Nov, Presenters: **Brock GB**
60. **Invited Lecturer**, ISSM, Cairo, Egypt, 2006 Sep, Presenters: **Brock GB**
61. **Invited Lecturer**, Northeast AUA, Ottawa, Ontario, Canada, 2006 Sep, Presenters: **Brock GB**
62. **Invited Lecturer**, Canadian Urology Association, Halifax, Nova Scotia, Canada, 2006 Jun, Presenters: **Brock GB**
63. **Invited Lecturer**, Grand River General Hospital, Kitchener, Ontario, Canada, Grand Rounds, 2006 Jun, Presenters: **Brock GB**
64. **Invited Lecturer**, St. Thomas General Hospital, St. Thomas, Ontario, Canada, Grand Rounds, 2006 Jun, Presenters: Brock GB`
65. **Visiting Professor**, Queen's University, Kingston, Ontario, Canada, 2006 Jun, Presenters: **Brock GB**
66. **Invited Lecturer**, American Urological Association, Atlanta, Georgia, United States, 2006 May, Presenters: **Brock GB**
67. Aging Male Conference, Salzburg, 2006 Feb 8, Presenters: **Brock GB**.

68. College of Physicians and Surgeons Review Panel. 2006 Jan 10, Presenters: **Brock GB**.
69. ESSM (European Society for Sexual Medicine) Copenhagen, December 4-7, 2005. 2005, Presenters: **Brock GB**.
70. Treatment of Premature Ejaculation Primarily Benefits the Partner. Sexual Medicine Society of North America, Inc. 2005 Fall Meeting, New York City, New York, November 17-20, 2005. 2005, Presenters: **Brock GB**.
71. What's up with the newest developments in erectile dysfunction research? Lawson Seminar Series, SJHC. October 25, 2005. 2005, Presenters: **Brock GB**.
72. Effective Management of Erectile Dysfunction. Urology Nurses Forum, April 12, 2005. 2005, Presenters: **Brock GB**.
73. International Conference on Prostate Cancer, Montego Bay, Jamaica, March 10-13, 2005. 2005, Presenters: **Brock GB**.
74. State of the Art Update on ED. Aging Male Conference, Vancouver, BC, February 4-5, 2005. 2005, Presenters: **Brock GB**.
75. Current Problems in Urology. Mt. Tremblant, Quebec, January 27, 2005. 2005, Presenters: **Brock GB**.
76. **Visiting Professor**, University of Manitoba, Winnipeg, Manitoba, Canada, Guest Professor - Resident Research Day, 2004 Nov, Presenters: **Brock GB**
77. **Invited Lecturer**, Journal of Sexual Medicine, Buenos Aires, Argentina, The three PDE5 inhibitors are not distinctly different - Journal of Sexual Medicine Debate, 2004 Oct, Presenters: **Brock GB**
78. **Invited Lecturer**, St. Thomas Elgin General Hospital, St. Thomas, Ontario, Canada, Grand Rounds, 2004 Mar, Presenters: **Brock GB**
79. **Invited Lecturer**, London Prostate Cancer Support Group, London, Ontario, Canada, 2004 Jan, Presenters: **Brock GB**
80. Oncology: The Impact of Radio therapy on ED: a management update. LRCC Rad. November 30, 2004. 2004, Presenters: **Brock GB**.
81. University of Manitoba, Winnipeg, Manitoba – Resident Research Day, November 23-24, 2004. 2004, Presenters: **Brock GB**.
82. New Treatment Options in the Treatment of Chronic Bacterial Prostatitis. Janssen-Ortho, London, November 15, 2004. 2004, Presenters: **Brock GB**.
83. New Treatment Options in the Treatment of Chronic Bacterial Prostatitis. Janssen-Ortho, Kitchener, November 9, 2004. 2004, Presenters: **Brock GB**.
84. The Three PDE5 Inhibitors are not distinctly different. Sponsored by: The Journal of Sexual Medicine.– International Society of Sexual Impotence Research – Buenos Aires/Argentina, October 29, 2004. 2004, Presenters: **Brock GB**.
85. Association of Radiotherapists, Halifax, Nova Scotia, September 9, 2004. 2004, Presenters: **Brock GB**.
86. St. Thomas General Hospital, March 27, 2004. 2004, Presenters: **Brock GB**.
87. Hong Kong Urologic Association, Hong Kong, March 11-12, 2004. 2004, Presenters: **Brock GB**.
88. London Prostate Cancer Support Group – LRCC, January 26, 2004. 2004, Presenters: **Brock GB**.
89. Society of Urologic Surgeons of Ontario, Toronto, November 11, 2003. 2004, Presenters: **Brock GB**.
90. **Invited Lecturer**, Canadian Cardiovascular Society, Toronto, Ontario, Canada, Sex and the heart, 2003 Oct, Presenters: **Brock GB**
91. **Invited Lecturer**, Philippines Urological Association, Philippines, New therapies for erectile dysfunction, 2003 Oct, Presenters: **Brock GB**
92. **Invited Lecturer**, NE American Urological Association, Halifax, Nova Scotia, Canada, Tadalafil, 2003 Sep, Presenters: **Brock GB**

93. **Invited Lecturer**, WHO Consensus Conference, Paris, France, Tadalafil, 2003 Jun, Presenters: **Brock GB**
94. Sex and the Heart. Canadian Cardiovascular Society (CCS), Toronto, October 29, 2003. 2003, Presenters: **Brock GB**.
95. Erectile Dysfunction: Merging Therapy. Mid Atlantic AUA, Miami, October 29, 2003. 2003, Presenters: **Brock GB**.
96. Canadian Diabetes Society, Ottawa, October 16, 2003. 2003, Presenters: **Brock GB**.
97. SMSNA, Denver, October 10 – 12, 2003. 2003, Presenters: **Brock GB**.
98. New Therapies for Erectile Dysfunction. Philippines Urological Association, September 29, October 6, 2003. 2003, Presenters: **Brock GB**.
99. Lilly Advisory Board, New York, September 20 – 21, 2003. 2003, Presenters: **Brock GB**.
100. Advisory Board, Pfizer, Toronto, September 12, 2003. 2003, Presenters: **Brock GB**.
101. Tadalafil. NE Section AUA, Halifax, September 3 - 7, 2003. 2003, Presenters: **Brock GB**.
102. Tadalafil. WHO Consensus Conference, Paris, June 26 pm - July 6, 2003. 2003, Presenters: **Brock GB**.
103. CUA, Montreal, June 21, 2003 - June 24, 2003. 2003, Presenters: **Brock GB**.
104. Levitra. Bayer, Prague May 29 pm - June 1, 2003. 2003, Presenters: **Brock GB**.
105. Sex and Surgery and the Future of ED Treatment. Pfizer, Kitchener, May 7, 2003. 2003, Presenters: **Brock GB**.
106. AUA, Chicago, April 24, 2003 - April 29, 2003. 2003, Presenters: **Brock GB**.
107. Residents' Day, April 11, 2003. 2003, Presenters: **Brock GB**.
108. American Geriatric Psychiatric Meeting, Hawaii, 03/03. 2003, Presenters: **Brock GB**.
109. New York, Cornell University, 02/03. 2003, Presenters: **Brock GB**.
110. **Invited Lecturer**, St. Thomas Elgin General Hospital, St. Thomas, Ontario, Canada, Management of ED in the family practice, 2002 Jun, Presenters: **Brock GB**
111. ESSIR, Hamburg, Germany, 12/02. 2002, Presenters: **Brock GB**.
112. Dr. Vinden, SWASA, London, 11/02. 2002, Presenters: **Brock GB**.
113. Puerto Rico Urology Association, San Juan, Puerto Rico, 11/02. 2002, Presenters: **Brock GB**.
114. The Management of MSD and other Critical Issues in Men's Health. The 7th annual Symposium, Columbia University, Los Angeles, 11/02. 2002, Presenters: **Brock GB**.
115. Levitra Advisory Board, Miami, 10/02. 2002, Presenters: **Brock GB**.
116. South Central AUA, Colorado Springs, 10/02. 2002, Presenters: **Brock GB**.
117. Train the Trainer. Pfizer Pro C, Montreal, 09/02. 2002, Presenters: **Brock GB**.
118. What's New is Prostate CA. London Regional Cancer Centre and LHSC Public Forum, 09/02. 2002, Presenters: **Brock GB**.
119. Columbia University, Chicago, 09/02. 2002, Presenters: **Brock GB**.
120. ISSIR, Montreal, 09/02. 2002, Presenters: **Brock GB**.
121. Lilly Global Medical Conference, Indianapolis, 09/02. 2002, Presenters: **Brock GB**.
122. ED CME – GPs and Specialists Southwestern Ontario, Niagara Falls, 07/02. 2002, Presenters: **Brock GB**.

123. ED – Lilly Tour – Cialis – Asian countries, Seoul, Taiwan, Singapore, 07/02. 2002, Presenters: **Brock GB.**
124. Prostate Cancer Support Group – ED Options, London Regional Cancer Centre, 07/02. 2002, Presenters: **Brock GB.**
125. Erectile Dysfunction Roundtable, Windsor, Ontario, 06/02. 2002, Presenters: **Brock GB.**
126. Management of ED in the Family Practice. St. Thomas Elgin, 06/02. 2002, Presenters: **Brock GB.**
127. Neurogenic Basis to Erectile Dysfunction. Neurology residents, UWO, 06/02. 2002, Presenters: **Brock GB.**
128. ED Symposia - the integrated analysis of Cialis. Post graduate symposium, Orlando, 5/02. 2002, Presenters: **Brock GB.**
129. State of the Art. Comprehensive Conference of Sexual Medicine, Vancouver, 4/02. 2002, Presenters: **Brock GB.**
130. The role of intracavernous injection therapy. Monte Carlo-MSD, 4/02. 2002, Presenters: **Brock GB.**
131. Erectile Dysfunction Symposium, European Urology Association, Birmingham, 2/02. 2002, Presenters: **Brock GB.**
132. Quest faculty, residents preparatory course, London, 2/02. 2002, Presenters: **Brock GB.**
133. **Invited Lecturer**, St. Joseph's Health Care, London, Ontario, Canada, ED update for internal medicine, 2001 Sep, Presenters: **Brock GB**
134. **Symposia Chair**, Canadian Urology Association, Toronto, Ontario, Canada, Update on ED, 2001 Jun, Presenters: **Brock GB**
135. **Invited Lecturer**, Gold Medal Conference, Indianapolis, Indiana, United States, Canadian dose-ranging study: Cialis taken as needed, 2001 May, Presenters: **Brock GB**
136. **Invited Lecturer**, Maritime Uro-Oncology Meeting, Cornerbrook, Canada, Erectile dysfunction associated with prostate cancer treatment, 2001 Feb, Presenters: **Brock GB**
137. International Sexual Health Council, Venice, Italy, 12/01. 2001, Presenters: **Brock GB.**
138. Prostatitis and Peyronie's Disease. Cambridge, Ontario, 10/01. 2001, Presenters: **Brock GB.**
139. The workup of ED & Ejaculatory dysfunction: approaches to management. Toronto Update, 09/01. 2001, Presenters: **Brock GB.**
140. Role of intracavernous injection for ED. European Society of Impotence Research, Rome Italy, 10/01. 2001, Presenters: **Brock GB.**
141. ED Update for Internal Medicine. Joseph's Health Care, 09/01. 2001, Presenters: **Brock GB.**
142. Prostate Cancer Support Group, London Regional Cancer Centre, 08/01. 2001, Presenters: **Brock GB.**
143. Update on ED. Canadian Urological Association Meeting, Toronto, Ontario, 06/01. 2001, Presenters: **Brock GB.**
144. The work-up of ED. American Urological Association Meeting - Anaheim, California, Post Graduate Course, 06/01. 2001, Presenters: **Brock GB.**
145. Canadian Dose-Ranging Study: Cialis Taken as Needed. Gold Medal Conference, Indianapolis, 05/01. 2001, Presenters: **Brock GB.**
146. Pharmacists Role in ED. London, Ontario, 05/01. 2001, Presenters: **Brock GB.**
147. Obstructive and Non Obstructive Azoospermia. Department of Obstetrics and Gynaecology. 03/01. 2001, Presenters: **Brock GB.**
148. Erectile Dysfunction Associated with Prostate Cancer Treatment. Maritime Uro-Oncology Meeting, Cornerbrook, Newfoundland, 02/01. 2001, Presenters: **Brock GB.**
149. **Visiting Professor**, Mexican Urological Association, Mexico City, Mexico, The treatment of Peyronie's disease and new treatment approaches to ED, 2000 Jun, Presenters: **Brock GB**

150. ED symposia. ISSIR, Perth, Australia, 12/00. 2000, Presenters: **Brock GB.**
151. New developments in ED. Sudbury, Ontario, 11/00. 2000, Presenters: **Brock GB.**
152. The Epidemiology of ED. ISSIR Symposia, Singapore, 11/00. 2000, Presenters: **Brock GB.**
153. New developments in the field of ED. Rochester, New York, 10/00. 2000, Presenters: **Brock GB.**
154. What today's Urologist and ED specialist needs to know. Kelowna, British Columbia, 10/00. 2000, Presenters: **Brock GB.**
155. ED new developments in the field. Calgary, Alberta, 10/00. 2000, Presenters: **Brock GB.**
156. What Investigations Should We be Performing in the 21st Century for Men with Sexual Dysfunction? Toronto, Ontario - University of Toronto - Continuing Education Andrology, 09/00. 2000, Presenters: **Brock GB.**
157. Newest Advances in the Treatment of Erectile Dysfunction. Toronto, Ontario - University of Toronto - Continuing Education Andrology, 09/00. 2000, Presenters: **Brock GB.**
158. SEX, How the Experts Do It. Toronto, Ontario - University of Toronto - Continuing Education Andrology, 09/00. 2000, Presenters: **Brock GB.**
159. ED treatment approach towards optimizing therapy. Northeast Section AUA, Pittsburgh, 09/00. 2000, Presenters: **Brock GB.**
160. The physiology of ED. Chicago, 08/00. 2000, Presenters: **Brock GB.**
161. **Visiting Professor**, The treatment of Peyronie's Disease and New treatment approaches to ED. Mexican Urological Association, Mexico City, Mexico, 06/00. 2000, Presenters: **Brock GB.**
162. ED Symposia. Canadian Urological Association Meeting - 2000 - Kelowna, British Columbia, 08/00. 2000, Presenters: **Brock GB.**
163. ED after Prostate Treatment. Woodstock Prostate Support Meeting, 06/00. 2000, Presenters: **Brock GB.**
164. Mexican Urological Association Meeting - 2000 - Mexico City, Mexico, 06/00. 2000, Presenters: **Brock GB.**
165. The Role of PSA. LHSC, 06/00. 2000, Presenters: **Brock GB.**
166. The Role of Imaging and ED. Ultrasound Technicians of South Western Ontario, 05/00. 2000, Presenters: **Brock GB.**
167. New developments in ED treatment. Ontario Medical Association Meeting – Urology section, 05/00. 2000, Presenters: **Brock GB.**
168. American Urological Association Meeting – Postgraduate course - Atlanta, Georgia, 04/00. 2000, Presenters: **Brock GB.**
169. ED symposium. Brazilian Urological Association, Brazil, 11/99. 1999, Presenters: **Brock GB.**
170. New Developments in treating ED. Canadian Association of Gerontology, Ottawa, 11/99. 1999, Presenters: **Brock GB.**
171. The role of injection therapy. Male Sexual Dysfunction, Los Angeles, 10/99. 1999, Presenters: **Brock GB.**
172. LRCC, London, 10/99. 1999, Presenters: **Brock GB.**
173. LRCC, Prostate Cancer Support Group, London, 10/99. 1999, Presenters: **Brock GB.**
174. Uro-Oncology Retreat, Niagara Falls, 10/99. 1999, Presenters: **Brock GB.**
175. McGill University, 50th Anniversary Refresher CME, Montreal, 10/99. 1999, Presenters: **Brock GB.**
176. SLAI - Latin American Urological Society of Impotence, Acapulco, 10/99. 1999, Presenters: **Brock GB.**
177. Psychiatric Update, Niagara Falls, 08/99. 1999, Presenters: **Brock GB.**

178. Developments in ED therapy. CME, Chatham, 07/99. 1999, Presenters: **Brock GB.**
179. ED Conference, CMSHC Symposium, Regina, 06/99. 1999, Presenters: **Brock GB.**
180. ED Conference, CMSHC Symposium, Winnipeg, 06/99. 1999, Presenters: **Brock GB.**
181. Educational ED symposia- Chair, CUA - London, Ontario, 06/99. 1999, Presenters: **Brock GB.**
182. The role of nonhormonal oral therapies on ED. International Consultation on ED - Paris, France – WHO, 06/99. 1999, Presenters: **Brock GB.**
183. ED Conference – Ottawa, 05/99. 1999, Presenters: **Brock GB.**
184. AUA - Postgraduate course, Dallas, Texas, 05/99. 1999, Presenters: **Brock GB.**
185. New advances in treatment of ED for the community Urologist. Northern Ontario Community Urologists Meeting, Bracebridge, 05/99. 1999, Presenters: **Brock GB.**
186. New treatments in ED. Ottawa University, Ottawa, 05/99. 1999, Presenters: **Brock GB.**
187. ED Cardiology Program, Vancouver, 03/99. 1999, Presenters: **Brock GB.**
188. Main Pro C, Mississauga, 03/99. 1999, Presenters: **Brock GB.**
189. Main Pro C, Idlewyld Inn, London, 02/99. 1999, Presenters: **Brock GB.**
190. The College of Family Physicians of Canada, Alberta Chapter, 44th Annual Scientific Assembly, 02/99. 1999, Presenters: **Brock GB.**
191. The role of Testosterone and Andropause (Industry sponsored). Family Medicine Group, London, 11/98. 1998, Presenters: **Brock GB.**
192. ED Symposium, Canadian Male Sexual Health Council, Vancouver BC, 11/98. 1998, Presenters: **Brock GB.**
193. ED Symposium, Canadian Male Sexual Health Council, Toronto, ON, 11/98. 1998, Presenters: **Brock GB.**
194. NorthWest Urological Society, Ed Update: A Core Based Workshop, 11/98. 1998, Presenters: **Brock GB.**
195. Erectile Dysfunction - new trends for patients with Prostate CA. University of Western Ontario, Department of Urology Uro-Oncology Fall Retreat, Bayfield, Ontario, 10/98. 1998, Presenters: **Brock GB.**
196. MUSE - Its place in Erectile Dysfunction Treatment. Janssen Ortho, Niagara Region, 10/98. 1998, Presenters: **Brock GB.**
197. The Role of I.C. Therapy in ED. CME London, 10/98. 1998, Presenters: **Brock GB.**
198. The role of the GP in the treatment of ED. Pfizer Psychiatric Update, Toronto, 10/98. 1998, Presenters: **Brock GB.**
199. The role of the I.C. Treatment in ED. Medical therapies for ED Conference, Los Angeles, 10/98. 1998, Presenters: **Brock GB.**
200. Specialized fine tuning of ED. American College of Physicians and Surgeons, Orlando, Florida, 10/98. 1998, Presenters: **Brock GB.**
201. Drug Interactions and Risk Factors in the Erectile Dysfunction Patient. Erectile Dysfunction Round table, Vaughan Estate Toronto, Ontario, 09/98. 1998, Presenters: **Brock GB.**
202. The Current Place of Injection Therapy in the Treatment of ED. 4th Asian Congress in Urology, Singapore, 09/98. 1998, Presenters: **Brock GB.**
203. ED in the 21st Century. Seminar, Pelvic Floor Meeting, Montreal, 09/98. 1998, Presenters: **Brock GB.**
204. Testosterone and Prostate Cancer: An Update. Toronto, Ontario, 09/98. 1998, Presenters: **Brock GB.**

205. New Treatment approached for ED. Grand Rounds, The Jewish General Hospital, Montreal Quebec, 09/98. 1998, Presenters: **Brock GB.**
206. New Treatment for ED in Men with Prostate CA. Prostate Cancer Awareness Series, LHSC, Cancer Support Group, 09/98. 1998, Presenters: **Brock GB.**
207. The role of Testosterone in Andropause. London, Ontario, 07/98. 1998, Presenters: **Brock GB.**
208. Educational Session on ED, Chair, CUA Annual Meeting, Halifax, N.S. 06/98. 1998, Presenters: **Brock GB.**
209. **Visiting Professor**, New Developments in ED. University of British Columbia, Vancouver, 06/98. 1998, Presenters: **Brock GB.**
210. Oral therapy for ED. AUA Postgraduate Course, San Diego, 06/98. 1998, Presenters: **Brock GB.**
211. The role of Testosterone in ED. Montreal, Canada, 05/98. 1998, Presenters: **Brock GB.**
212. Family Medicine Forum, BPH & IGF, Royal Victoria Hospital, 05/98. 1998, Presenters: **Brock GB.**
213. The role of Sildenafil in Diabetic Men. Endocrinology Grand-Rounds, 04/98. 1998, Presenters: **Brock GB.**
214. IGF and the alterations of NOS isotopes with disease. Urology Research Seminar, Royal Victoria Hospital, Montreal, 03/98. 1998, Presenters: **Brock GB.**
215. The impact of new therapies for Erectile Dysfunction. Halifax, Nova Scotia, 03/98. 1998, Presenters: **Brock GB.**
216. The evolving therapeutic choice for ED. Saskatoon, Saskatchewan, 03/98. 1998, Presenters: **Brock GB.**
217. Up and Coming Developments in ED. Filipino Nurses Association Quebec, Montreal, 02/98. 1998, Presenters: **Brock GB.**
218. Patented Medicine Price Review Board Presentation Ottawa, Ontario, 01/98. 1998, Presenters: **Brock GB.**
219. Erectile Dysfunction Review, Nassau, Bahamas, 01/98. 1998, Presenters: **Brock GB.**
220. The role of alpha blockers on Urinary Flow. Urology Residents Meeting, Mikado, Montreal, 12/97. 1997, Presenters: **Brock GB.**
221. Erectile Dysfunction, The essentials for the Obs/Gyne Resident. Royal Victoria Hospital, Montreal, 12/97. 1997, Presenters: **Brock GB.**
222. New agents and Developments in Erectile Dysfunction. A specialty Workshop. Co-chairperson Seattle, Washington, North West Urology Assoc. 12/97. 1997, Presenters: **Brock GB.**
223. Round table Discussion - The role of androgens in man and women. Department of Psychiatry JGH, Dr. M. Segal, Chair, 11/97. 1997, Presenters: **Brock GB.**
224. Do the current ED guidelines make sense? Urology Update - University of Toronto, 11/97. 1997, Presenters: **Brock GB.**
225. Erectile dysfunction. 48th McGill University Annual Refresher Course for Family Medicine Update, Montreal, 11/97. 1997, Presenters: **Brock GB.**
226. Impotence in the 21st Century, approaches to new therapies. Lady Davis Institute for Medical Research, Montreal, 11/97. 1997, Presenters: **Brock GB.**
227. Diabetic Impotence: effect on transcription and translation of NOS. Canadian Society for Clinical Investigation (MRC-FRSQ), Royal College of Physicians and Surgeons, Vancouver, BC. 10/97. 1997, Presenters: **Brock GB.**
228. The evaluation of the Impotent Man. Family Medicine Review course, Montreal, 10/97. 1997, Presenters: **Brock GB.**
229. New Agents and Developments in Erectile Dysfunction. A specialty workshop. Co-chairperson, Phoenix, Arizona, 10/97. 1997, Presenters: **Brock GB.**

230. The work-up of the impotent man. Family Physician Update (CME Course 6 hours), 10/97. 1997, Presenters: **Brock GB**.
231. The role of fibrin glue as a transport vehicle for ROS in nerve trauma: an animal model. Expert workshop on new indications for fibrin glue, Vienna, Austria, 10/97. 1997, Presenters: **Brock GB**.
232. Erectile Dysfunction Update. Society of Urologic Surgeons of Western Ontario, Scarborough, Ontario, 09/97. 1997, Presenters: **Brock GB**.
233. Chair, special educational session on Impotence treatment for the next millennium, CUA meeting, Quebec City, 06/97. 1997, Presenters: **Brock GB**.
234. The role of androgens in erection and depression. Montreal General Hospital, Grand Rounds, Psychiatry, 06/97. 1997, Presenters: **Brock GB**.
235. Androgens and Male Health. St. Mary's Hospital Centre, Grand Rounds, Psychiatry, 06/97. 1997, Presenters: **Brock GB**.
236. BPH, the role of alpha blockade. Montreal West, Family Physicians, 05/97. 1997, Presenters: **Brock GB**.
237. Peyronie's disease and the role of androgens on erection. New Orleans, LA. Continuing Medical Education Course, (Educational course at the annual meeting of the AUA, 04/97. 1997, Presenters: **Brock GB**.
238. Androgens and Sexual Function. Douglas Hospital Centre, 03/97. 1997, Presenters: **Brock GB**.
239. Effect of radiotherapy on the neurovascular mechanisms essential for erectile function. Radiotherapy Grand Rounds, Jewish General Hospital, 02/97. 1997, Presenters: **Brock GB**.
240. The use of a no-needle jet-injector for impotence: an animal model. Schwartz Pharma Symposium, Dusseldorf, Germany, 01/97. 1997, Presenters: **Brock GB**.
241. New trends in erectile dysfunction. Victoria Grand Rounds, Victoria, B.C. 12/96. 1997, Presenters: **Brock GB**.
242. Up and coming issues related to male erectile dysfunction. Edmonton, Alberta. Univ. Alberta, Urology Grand rounds, 11/96. 1996, Presenters: **Brock GB**.
243. What's new and exciting in erectile dysfunction? Winnipeg, Manitoba, Manitoba Grand Urology Rounds, 09/96. 1996, Presenters: **Brock GB**.
244. Sexual dysfunction and Parkinson's disease. Parkinson's Society, Montreal, 03/96. 1996, Presenters: **Brock GB**.
245. Erectile dysfunction, review. McGill Family Med. Course, 02/96. 1996, Presenters: **Brock GB**.
246. Erectile dysfunction is it hormone dependent? Lady Davis Institute Research Conference, Principle Investigators, 02/95. 1995, Presenters: **Brock GB**.
247. Erections just say no! Canadian Andrology and Fertility Society, St. Andrew's, Nova Scotia, 09/94. 1994, Presenters: **Brock GB**.
248. The treatment of erectile dysfunction after Prostate Cancer. Jewish General Hospital Cancer Support Group, 12/93. 1993, Presenters: **Brock GB**.
249. **Invited Lecturer**, Department of Surgery Research Day, Canada, Update of ED and PD, Presenters: Brock

TEACHING ACTIVITIES

Innovations in Teaching

2007 - 2008 Course Director, Postgraduate, OSCE exam for UWO and Macmaster urology residents, 12 residents from Western and Mac were given a formal OSCE, surgery, urology, Hours: 25, 12, The feedback was very positive and formal results were provided to the program directors at UWO and Mac

TEACHING RESPONSIBILITIES

Postgraduate Medical Education

Admin

Examiner - Royal College

2008 Jul 1 - 2009 Jun 30 Royal College Urology Exam Committee as a Nucleus Member

2007 Jul 1 - 2008 Jun 30 St. Joe's, Prior to setting the Royal College exam in November I routinely meet with the chief residents on 3-4 occasions to review pertinent study techniques and likely questions in Andrology, trauma and female urology. chief residents, Number of Students: 2, Total Hours: 6

Undergraduate Medical Education

Courses

Examiner - Clerkship Oral Exams

2013 Aug 14 St. Joseph's Health Care, Clerkship Orals, Total Hours: 2

2012 Aug 15 St. Joseph's Health Care, Clerkship Orals, Total Hours: 2

2011 Aug 17 St. Joseph's Health Care, Clerkship Orals, Total Hours: 2

2010 May 19 St. Joseph's Health Care, Clerkship Orals, Total Hours: 2

2009 Feb 18 St. Joseph's Health Care, Clerkship Orals, Total Hours: 2

2006 Aug 16 - 2006 Nov 22 Total Hours: 1

Instructor - Clerkship Seminar

2014 Oct 27 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 1

2014 Jun 16 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 1

2014 May 5 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 1

2014 Feb 3 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 1

2013 Oct 28 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 1

2013 Jul 15 University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2

2013 Mar 18	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2013 Jan 7	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2012 Oct 22	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2012 Jul 9	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2012 May 14	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2012 Jan 2	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2011 Oct 17	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2011 Jul 15	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2011 Apr 18	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2011 Jan 17	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2010 Nov 1	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2010 Jul 19	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2010 Apr 28	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2010 Jan 4	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2009 Oct 19	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2009 Jun 3	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2
2009 Apr 1	University Hospital, Prostate Disorders and Voiding Dysfunction, Total Hours: 2

Instructor - Clinical Methods

2007 Feb 20	Block I, Total Hours: 1
-------------	-------------------------

Instructor - Clinical Methods - Surgery

2012 Feb 1	St. Joseph's Health Care, Week Three, Total Hours: 3
------------	--

Supervisor / Examiner - OSCE Year 2 or Year 4

2011 Jan 13	St. Joseph's Health Care, Year 4, Total Hours: 5
2007 Jan 18	Total Hours: 1

Instructor - Classroom Teaching (excluding PCL/Clinical Methods/Clinical Skills)

2007 Nov 23	Case-based Lecture: Medicine - Urology: Andrology
-------------	---

Continuing Medical Education

Courses

Invited Lecturer

2007 Jul 1 - 2008 Jun 30	Toyko, Japanese Urology Association, Number of Students: 100, Total Hours: 2
--------------------------	--

2007 Jul 1 - 2008 Jun 30	Greece, CME course Greece, Number of Students: 100, Total Hours: 6
2007 Jul 1 - 2008 Jun 30	Toronto, University of Toronto Update on Penile Rehabilitation Oct 2007, Number of Students: 20, Total Hours: 2
2007 Jul 1 - 2008 Jun 30	Portugal, ESSM, Number of Students: 1500, Total Hours: 1
2007 Jul 1 - 2008 Jun 30	Chicago, SMSNA, Number of Students: 350, Total Hours: 1
2007 Jul 1 - 2008 Jun 30	St Johns NFLD, Canadian Cancer Society- Prostate Cancer and ED, Total Hours: 1

Organizer - CME course

2009 Jun	Video OSCE for CUA and GPs: PE
2009 Jun	Video OSCE for CUA and GPs: ED
2009 Jun	Video OSCE for CUA and GPs: Prostate Cancer
2009 May	St Joe's Urology, OSCE Development for Residents and Examination, All Urology Residents participated, Number of Students: 10, Total Hours: 10
2007 Jul 1 - 2008 Jun 30	St Josephs, OSCE for Macmaster and UWO Urology Residents, Number of Students: 15, Total Hours: 6

Presenter - Faculty Development Course / Workshop

2007 Jul 1 - 2008 Jun 30	Tampa Florida, ISSM Tampa Florida, Number of Students: 200, Total Hours: 3
--------------------------	--

Visiting Professor

2008 Jul - 2009 Jul	Japanese Andrology Society
2007 Jul 1 - 2008 Jun 30	University of Alberta, April 2008, Number of Students: 30, Total Hours: 2
2007 Jul 1 - 2008 Jun 30	Stockholm, Karolinska Sweden , May 2008, Number of Students: 20, Total Hours: 1

SUPERVISION AND MENTORING

Supervision

Master's Level Graduate Student Research Supervision

1997 - 1998	Wendy Fox, MSc candidate, <i>Is an inhibitory protein acting on neuronal nitric oxide synthase in disease states.</i> , Thesis Co-Supervisor
1996 - 2000	Howard Lieberman, MSc, <i>The impact of vasoactive intra-penile drug infusion on neuronal nitric oxide synthase and vessel response.</i> , Thesis Co-Supervisor
1995 - 1996	Scott Merlin, MSc, <i>The impact of radiotherapy on endothelin production within the penile vasculature.</i> , Thesis Co-Supervisor
1994 - 1995	Philippe Spiess, MSc, <i>The role of neuronal nitric oxide inhibitors on penile vascular tone.</i> , Thesis Co-Supervisor

Postdoctoral Fellowship

2013 - 2014	Francisco Garcia, Andrology, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Clinical Fellow Supervisor
2012 - 2013	Joe King Lee, Andrology, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Clinical Fellow Supervisor
2010 - 2011	Eric Chung, Andrology, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Clinical Fellow Supervisor
2008 - 2009	tariq Al Shaiji, Andrology, Graduate and Postdoctoral Studies, surgery, urology, Formal, Grad Student / Postdoctoral Student Supervisor
2007 - 2008	Mahmoud Al Numi, Graduate and Postdoctoral Studies, surgery, urology, Formal, Clinical Fellow Supervisor
2005 - 2006	Kok Bin Lim, Andrology, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Clinical Fellow Supervisor
1996 - 1998	Mahmoud El-Naggar M.D. <i>Renal failure impairs erection through neuronal and endothelial mechanisms: An animal study.</i> , Clinical Fellow Supervisor
1996 - 1998	Tarek Abdel-Baky M.D. <i>The effect of diabetes on nNOS and eNOS and their mRNA.</i> , Clinical Fellow Supervisor
1995 - 1997	Raouf Seyam M.D. <i>A novel no-needle delivery system for erection: An animal model. The impact of Proscar and hormonal withdrawal on neuronal/endothelial NOS.</i> , Clinical Fellow Supervisor
1994 - 1996	L.M.Tu M.D. <i>The effect of repeated intracavernous injections on penile circulation.</i> , Clinical Fellow Supervisor
1993 - 1995	Peter Zvara M.D. <i>The role of testosterone on erectile function and the course of the cavernous nerve fibers.</i> , Clinical Fellow Supervisor

Postgraduate Student Supervision (Clinical)

1997 - 1998	Al-Said M.D. <i>The impact of Tisseel delivery of nerve growth factor on erectile preservation following direct nerve injury.</i> , Resident Research Supervisor
1997 - 1998	Kamal Pohar M.D. <i>Use of nerve growth factor and reactive oxygen scavengers on erectile function following nerve trauma.</i> , Resident Research Supervisor
1997	Carson Wong M.D. <i>An animal model of renal failure, the impact on erectile function.</i> , Resident Research Supervisor
1996 - 1997	Daniel Rosenstein M.D. <i>Does endothelin-1 rise following radiotherapy in the treatment of prostate cancer?</i> , Resident Research Supervisor
1995 - 1994	Peter Chan M.D. <i>A superselective nerve sparing radical prostatectomy in the rat.</i> , Resident Research Supervisor
1994	Pierre Karakiewicz M.D. <i>A novel nerve trauma model simulating the injury of the cavernous nerve from radical prostatectomy.</i> , Resident Research Supervisor
1994	Richard Sioufi M.D. <i>The role of testosterone withdrawal on erectile function: an animal model.</i> , Resident Research Supervisor

Undergraduate Research Supervision

2007 - 2008	Steven Taylor, Science, Biochemistry, Formal, Summer Student Supervisor
-------------	--

resident research

- 2007 - 2008 Peter Erdjelian, 12 month research into Peyronie's proteins, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Formal, **Resident Research Supervisor**
- 2007 - 2008 Trustin Domes, Peyronie's protein Seldi profile, Schulich School of Medicine & Dentistry, Department of Surgery, Division of Urology, Formal, **Resident Research Supervisor**

Resident Research Supervisor

- 2000 - 2005 Anthony Bella, Schulich School of Medicine & Dentistry, **Resident Research Supervisor**

Mentorship

Resident (Post Graduate Training)

- 2007 - 2008 Trustin Domes, Location: Lawson research, Graduate and Postdoctoral Studies, surgery, urology
- 2006 - 2008 Peter erdjelian, research studies, Location: Lawson research, Graduate and Postdoctoral Studies, surgery, urology

Fellow

- 2006 - 2008 Mohamed AL Numi, post-doc fellow, Location: St Joseph's, Graduate and Postdoctoral Studies, surgery, urology

OTHER ACTIVITIES

Other Noteworthy Activities

- 2004 CURC – Treasurer – Executive
- 2004 Chair – Scientific Committee 2007 Andropause Meeting in Montreal
- 2003 Sanofi, Advisory Board Member
- 2001 Bayer, Advisory Board Member
- 2000 ISSIR treasurer - 2002 Montreal Meeting
- 1999 Eli Lilly/ICOS, Advisory Board Member
- 1998 Pfizer, Advisory Board Member
- 1997 Janssen-Ortho Pharm, Advisory Board Member
- 1996 American Medical Systems, Advisory Board Member
- 2005 Royal College Exams - Ottawa
- 2001 UWO Urology Residents Day - Treasurer
- 1997 Young Urologists Association Meeting - Quebec City
- 1997 Canadian Male Sexual Health Council - Quebec City

1996	Performance Recognition Committee - Chairman, McGill Department of Urology
1996	Erectile dysfunction health professional network - Chairman Victoria, B.C.
1996	SLUG (St. Lawrence Urology Group) Meeting Chairman, Montebello Quebec
1995	McGill Urology Research Day - Meeting Chairman